Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal English
Coverage 105,887 Raw stories ingested 10,343 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 31s ago
  • FMP Forex News Fetch every 5 min 2m ago
  • CoinGecko News Fetch every 5 min 2m ago
  • FIO Stock News Fetch every 10 min 1m ago
  • Patria Stock News Fetch every 10 min 1m ago
  • Editorial rewrite Rewrite every minute 31s ago
  • Asset sync Assets every 1 hour 51m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Clear
Details Date Content Source
2026-07-24 06:59 8d ago
2026-07-23 09:00 9d ago
Starboard Debuts Iconic Retail Experiences Onboard Royal Caribbean's Legend of the Seas
RCL Royal Caribbean Cruises
FMP Stock News
Original source text
MIAMI--(BUSINESS WIRE)--Starboard today announced the debut of an expansive collection of immersive retail experiences onboard Royal Caribbean's Legend of the Seas.
2026-07-24 06:59 8d ago
2026-07-23 09:00 9d ago
Oceania Cruises® Spotlights Its Signature Wellness Discovery Tours
NCLH Norwegian Cruise Line
FMP Stock News
Original source text
Luxury Travelers Embrace the Rejuvenating Power of Travel Through Wellness Experiences Rooted in Local Traditions

Oceania Vista® sailing in Santorini, Greece, and yoga and stretch classes aboard Oceania Cruises' ships. Download high-resolution images here. (Credit: Oceania Cruises®)

, /PRNewswire/ -- From practicing tai chi in Bangkok, to dance therapy in Colombo, to yoga and wine tasting in Santorini, Oceania Cruises®, the world's leading destination- and culinary-focused luxury cruise line, invites discerning travelers to embrace a new era of exploration through its acclaimed Wellness Discovery Tours.

Yoga classes offered on Oceania Cruises Responding to a growing interest in wellness experiences, Oceania Cruises offers more than 50 Wellness Discovery Tours in destinations throughout Asia, Europe and South America, as luxury travelers are increasingly seeking journeys that allow them to learn new skills and explore the world differently. This signature collection of tours offers opportunities to engage with centuries-old healing traditions, mindfulness practices and local cultures across the globe.

"Travel has become one of the most powerful ways people invest in their wellbeing. It's a means of stepping outside of their usual routine to slow down, explore different cultures and destinations, and return home with a renewed perspective," said Jason Montague, Chief Luxury Officer of Oceania Cruises. "Our Wellness Discovery Tours are designed for those seeking to nurture their wellbeing and discover the rejuvenating power of travel. For today's luxury guest, travel is much more than movement from place to place – it is a journey of discovery, with every voyage offering the chance to expand horizons, deepen understanding and return home transformed by new perspectives."

Intended to inspire connection and enrichment, Oceania Cruises' small-group, wellness-oriented tours bring guests together with local specialists and like-minded travelers. Experiences range from mineral-rich baths and yoga to dance, power walking and culinary classes.

These shoreside encounters are complemented by a wealth of enriching experiences on board Oceania Cruises' intimate, luxurious ships. With culinary lectures, hands-on cooking classes and food and beverage pairing experiences, plus creative workshops in the Artist Loft, insightful guest speakers and performances by local musicians, guests can enjoy a diverse program designed to enhance their journey.

The enrichment options both ashore and on board are encompassed by the serenity of the adults-only environment aboard Oceania Cruises' boutique ships, allowing guests to explore an extraordinary array of destinations at their own pace and with like-minded travelers.

Highlights of Oceania Cruises Wellness Discovery Tours:

Ultimate Traditional Dance Therapy – Colombo, Sri Lanka: Release tension and lift your mood through Kandyan dance, learning the moves and rituals of Sri Lanka's national dance in an uplifting group setting. Saigonese Organic Food Tasting – Ho Chi Minh City, Vietnam: Savor organic teas and vegetarian cuisine, engaging with local experts and gaining insights into Vietnam's celebrated tea culture. Tai Chi at Viharn Sien Park – Bangkok, Thailand: Visit a serene urban park in the shadow of the temple Viharn Sien to practice the slow, fluid movements of tai chi, an ancient form of exercise improving strength, flexibility and balance. Healthy Stroll Along the Cliffs and Getxo – Bilbao, Spain: Traverse geologically rich cliff paths, pass 18th-century windmills and fortresses, and experience the Basque fishing village of Getxo – with time to enjoy local tapas and authentic culture. Thermal Baths of the Popes – Rome (Civitavecchia), Italy: Restore mind and body at Terme dei Papi, soaking in mineral-rich waters beloved by popes, artists and poets for centuries, set in the inspirational Italian countryside. Traditional Chinese Medicine Experience – Hong Kong, China: Consult with a traditional medicine doctor and try therapies such as acupuncture or cupping, learning ancient methods to promote relaxation and vitality. Yoga & Wine Tasting Overlooking Caldera – Santorini, Greece: Find tranquility with a meditative yoga session on a winery terrace, followed by tastings of Santorini's distinct vintages while admiring the breathtaking views. Tai Chi & Vegetarian Lunch at a Monastery – Hanoi, Vietnam: Experience mindful movement surrounded by spectacular natural beauty and spiritual heritage in a Buddhist monastery on Yen Tu Mountain. Volcanic Thermal Pools and Naples – Naples/Pompeii, Italy: Alternate between hot and cold pools, surrounded by ancient landscapes and timeless healing traditions. Patagonian Hot Springs & Fjord Cruise – Puerto Chacabuco, Chile: Invite relaxation and mindfulness with a journey through the Aysén Fjord by catamaran to the secluded Ensenada Perez Hot Springs, where Patagonian landscapes surround naturally heated pools. Oceania Cruises is celebrated for its personalized service, award-winning cuisine and a crew-to-guest ratio designed for exceptional comfort. With destination-intensive itineraries ranging from seven to 180 days, guests return home with renewed energy, inspiration and stories that last a lifetime.

For more information visit OceaniaCruises.com or call 855-OCEANIA.

About Oceania Cruises®

Oceania Cruises® is the world's leading destination- and culinary-focused luxury cruise line, celebrated for its port-rich voyages and authentic cultural and culinary experiences. The line's intimate, luxurious ships feature an adults-only environment, with a high proportion of spacious rooms and suites, calling on more than 600 marquee and boutique ports in more than 100 countries across seven continents, with destination-intensive itineraries ranging from seven to 180 days. Aboard the designer-inspired ships, guests enjoy personalized service supported by a strong crew-to-guest ratio, alongside The Finest Cuisine at Sea®, prepared by one of the highest chef-to-guest ratios at sea. Oceania Cruises® is also recognized as one of the world's most awarded cruise lines, with accolades spanning luxury, dining, service and destination experiences. Oceania Cruises® has five Sonata Class ships on order scheduled for delivery in 2027, 2029, 2032, 2035 and 2037. Oceania Cruises® is a wholly owned subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH).

SOURCE Oceania Cruises
2026-07-24 06:58 8d ago
2026-07-24 02:16 8d ago
American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
AXP American Express
FMP Stock News
Original source text
BenzingaEspaña

Italia

대한민국

日本

Français

SPY738.790.08%

QQQ693.540.23%

BTC/USD65313.520.4032%

DIA516.020.05%

GLD371.320.05%

TLT83.240.09%

Get Benzinga Pro Data & APIs

Events

Premarket

Advertise

Contribute

España

Italia

대한민국

日本

Français

BenzingaPremium Services Benzinga Edge

Benzinga Pro

Benzinga Research

Benzinga APIs

Financial News Financial News

Large Cap Stocks

Small-Cap Stocks

Insider Trades

Earnings

Technology

AI News

Personal Finance

ETF News

Crypto News

Dividend News

Latest Rumors

Latest Offerings News

Investment Ideas Investment Ideas

Stock of the Day

Stock Whisper Index

Analyst Ratings

Analyst Color

Financial Advisors

Government Trades

Trading Ideas

Stock Screener

Markets Markets

Premarket Movers

After Hours

Options

ETFs

Commodities

Prediction Markets

Private Markets

Bonds

Futures

Forex

Top Stocks Top Stocks

Apple (AAPL)

Tesla (TSLA)

Amazon (AMZN)

Nvidia (NVDA)

Alphabet (GOOGL)

Meta Platforms (META)

Microsoft (MSFT)

StreetTracks Gold Shares (GLD)

IBIT Bitcoin Trust (IBIT)

Top Value Stocks

Top Momentum Stocks

Top Growth Stocks

Top Quality Stocks

Learn Learn

Investing Guides

Personal Finance

Mortgages

Best Credit Cards

Best Dividend Stocks

Best Swing Trade Stocks

ResearchMy StocksToolsFree Benzinga Pro Trial Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Events Calendar

FDA Calendar

Guidance Calendar

IPO Calendar

M&A Calendar

Unusual Options Activity Calendar

SPAC Calendar

Stock Split Calendar

Trade Ideas

Stock Reports

Insider Trades

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Heatmaps

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Most Shorted

Largest Increase

Largest Decrease

Calculators

Options Profit Calculator

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Covered Call Calculator

Cash-Secured Put Calculator

Long Call Calculator

Long Put Calculator

Screeners

Stock Screener

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

SPY738.790.08%

QQQ693.540.23%

BTC/USD65313.520.4032%

DIA516.020.05%

GLD371.320.05%

TLT83.240.09%

July 24, 2026 2:16 AM 1 min read

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Check out our premarket coverage here

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Posted In:

MarketsTrading IdeasPre-Market OutlookLong IdeasNewsEarningsEquitiesMarket SummaryStocks To Watch

Connect With Us

About Benzinga

About UsCareersAdvertiseContact UsMarket Resources

Advanced Stock Screener ToolsOptions Trading Chain AnalysisComprehensive Earnings CalendarDividend Investor Calendar and AlertsEconomic Calendar and Market EventsIPO Calendar and New ListingsMarket Outlook and AnalysisWall Street Analyst Ratings and TargetsTrading Tools & Education

Benzinga Pro Trading PlatformOptions Trading Strategies and NewsStock Market Trading Ideas and AnalysisTechnical Analysis Charts and IndicatorsFundamental Analysis and ValuationDay Trading Guides and StrategiesLive Investor EventsPre-market Stock Analysis and NewsCryptocurrency Market Analysis and NewsRing the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions Do Not Sell My Personal Data/Privacy PolicyDisclaimer Service StatusSitemap©

2026

Benzinga | All Rights Reserved
2026-07-24 06:57 8d ago
2026-07-24 02:15 8d ago
Charter Communications Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
CHTR Charter Communications
FMP Stock News
Original source text
Charter Communications, Inc. (NASDAQ:CHTR) will release its second quarter earnings report before the opening bell on Friday, July 24.

Analysts expect the Stamford, Connecticut-based company to report quarterly earnings of $10 per share, up from $9.18 per share in the year-ago period. The consensus estimate for Charter Communications’ quarterly revenue is $13.51 billion. It reported $13.77 billion last year, according to Benzinga Pro.

On April 24, Charter Communications reported worse-than-expected first-quarter EPS results.

Charter Communications shares fell 2.1% to close at $126.50 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying CHTR stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-24 06:54 8d ago
2026-07-24 06:44 8d ago
Německo: Spotřebitelská důvěra dle GfK dosáhla v srpnu -29,6 b. při očekávání -28,5 b. FIO Stock News
Original source text
Německo: Spotřebitelská důvěra dle GfK dosáhla v srpnu -29,6 b. při očekávání -28,5 b.
2026-07-24 06:54 8d ago
2026-07-24 06:46 8d ago
Moneta Money Bank za 2Q 2026 dodala čistý zisk 1,8 mld. Kč a navyšuje celoroční výhled
MONET Moneta
FIO Stock News
Original source text
24.7.2026 08:46, BAAGECBA

Moneta Money Bank představila výsledky za 2Q 2026, v 10:00 se koná konferenční hovor. Čistý zisk za 2Q dosáhl 1,8 mld. Kč a management o 200 mil. Kč navýšil celoroční výhled. Výsledky hodnotíme neutrálně.

Výsledky hospodaření Moneta Money Bank za 2Q 2026 v mil. Kč 2Q 2026 Konsensus trhu 2Q 2025 Čisté úrokové výnosy 2 644  2 587 2 421 Čisté poplatky a provize  906 863 818 Ostatní provozní výnosy  142 175 173 Provozní výnosy 3 692  3 625 3 412 Provozní náklady  (1 367) (1 387) (1 375) Provozní zisk  2 325 2 238 2 037 Náklady na riziko  (254) (209) (117) Čistý zisk  1 763 1 718 1 628 Výsledky za 2Q 2026 Čisté úrokové výnosy ve 2Q dosáhly 2 644 mil. Kč, meziročně o 9 % více, mírně nad naším očekáváním ve výši 2 595 mil. Kč. Růst byl tažen především vyšším úvěrovým portfoliem.

Čisté úrokový výnosy Moneta Money Bank

Čisté poplatky a provize meziročně vzrostly o 11 % především díky distribuci investičních produktů.

Ostatní provozní výnosy naopak meziročně poklesly o 18 % na 142 mil. Kč.

Celkově tak Moneta za 2Q dosáhla provozních výnosů 3 692 mil. Kč, lehce nad naším očekáváním ve výši 3 632 mil. Kč.

Provozní náklady zůstaly meziročně na podobné úrovni, když vyšší mzdové náklady byly kompenzovány nižšími administrativními náklady a odpisy.

Provozní náklady Moneta Money Bank ve 2Q 2026

Na provozní úrovni banka reportovala zisk ve výši 2 325 mil. Kč při našem odhadu ve výši 2 253 mil. Kč.

Náklady na riziko v 2Q 2026 dosáhly výše 254 mil. Kč.

Celkově tak Moneta reportovala 8% meziroční růst čistého zisku na 1 763 mil. Kč, na úrovni našeho očekávání ve výši 1 765 mil. Kč.

Čistý zisk Moneta Money Bank za 2Q 2026

Čistý zisk za první polovinu letošního roku vzrostl na 3 346 mil. Kč, meziročně +8 %.

Čistý zisk Moneta Money Bank za 1H 2026

Klientské úvěry vzrostly o 9,1 % na 310 mld. Kč, zatímco klientské vklady vzrostly meziročně o 3,7 % na 454 mld. Kč.

Moneta dále reportovala kapitálovou přiměřenost 20 % a návratnost hmotného kapitálu (ROTE) 23,3 %.

Výhled Management potvrdil střednědobý výhled a pro letošní rok očekává, že dosáhne čistého zisku 6,8 mld. Kč, tedy o 200 mil. Kč více.

Střednědobý výhled Moneta Money Bank, zdroj: Moneta Money Bank

Hodnocení výsledkového reportu Čisté úrokové výnosy se meziročně zvýšily o 9 % a mírně předčily naše očekávání, když byly taženy velmi solidním růstem úvěrového portfolia. Management nadále drží provozní náklady pevně pod kontrolou. Provozní zisk byl mírně nad našimi odhady, naopak náklady na riziko vyšší, než jsme očekávali. Na úrovni čistého zisku Moneta dodala námi odhadovaných téměř 1,8 mld. Kč. Navýšení celoročního výhledu čistého zisku o 200 mil. Kč na 6,8 mld. Kč je v souladu s naší projekcí na letošní rok. Výsledkový report hodnotíme neutrálně.

Akcie Monety (BAAGECBA) včera uzavřely na pražské burze na 188,80 Kč a na RM-SYSTÉMu na 189 Kč.

Zdroj: Moneta Money Bank

Karel Nedvěd, Fio banka, a.s.

Související odkazy Projekce hospodaření Moneta Money Bank za 2Q 2026 Moneta: Komerční banka nastavila cílovou cenu na 192 Kč při doporučení „Držet“ Moneta: PKO BP Securities zvyšuje cílovou cenu ze 149 Kč na 200 Kč s novým doporučením "hold" Moneta Money Bank vydala nástroj vedlejšího kapitálu Tier 1 (AT1) Manažerské obchody: V květnu byl aktivní manažer Moneta Money Bank
2026-07-24 06:54 8d ago
2026-07-23 09:00 9d ago
General Mills Brings the Magic of Harry Potter™ Home with New Treats from Betty Crocker and Pillsbury
GIS General Mills
FMP Stock News
Original source text
MINNEAPOLIS--(BUSINESS WIRE)--Wizards, witches and Muggles alike can bring a little magic into their homes with new and returning Harry Potter-inspired products from Pillsbury and Betty Crocker. Arriving at retailers nationwide just in time for a season full of Harry Potter celebrations, this lineup is made for new ways to experience the beloved stories at home. With millions of fans around the globe, Harry Potter has become a cultural phenomenon that continues to bring families together. With.
2026-07-24 06:49 8d ago
2026-07-23 06:45 9d ago
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
LLY Eli Lilly & Co
FMP Stock News
Original source text
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks

Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.

"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. We look forward to working with regulators as they evaluate this first-of-its-kind medicine."

In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight. Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.

TRIUMPH-2 Efficacy Estimand Results in Participants with Obesity and Type 2 Diabetes1

Primary Endpoint at 80 Weeks 

Retatrutide 4 mg

Retatrutide 9 mg

Retatrutide 12 mg

Placebo

Percent change in body weight from avg. baseline of 106.4 kg (234.6 lbs; BMI of 38.2 kg/m²)i

-12.7% (-13.5 kg; -29.8 lbs) 

-19.1% (-20.6 kg; -45.4 lbs) 

-20.8% (-22.5 kg; -49.6 lbs) 

-4.0% (-4.2 kg; -9.3 lbs)

Key Secondary Endpoint at 80 Weeks

Change in A1C from a baseline of 7.7%

-1.4‌%

-1.6‌%

-1.5‌%

-0.2‌%

iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint.

In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks.

In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).

In TRIUMPH-3, retatrutide meaningfully reduced certain cardiovascular risk factors, with the highest dose delivering average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 7.5 in (19.0 cm) in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP).

TRIUMPH-3 Efficacy Estimand Results in Participants with Severe Obesity and Established Cardiovascular Disease1

Primary Endpoint at 80 Weeks

Retatrutide 9 mg

Retatrutide 12 mg

Placebo

Percent change in body weight from avg. baseline of 111.4 kg (245.6 lbs; BMI of 40.4 kg/m²)

-21.6% (-23.9 kg; -52.7 lbs) 

-22.6% (-25.3 kg; -55.8 lbs) 

-3.2% (-3.5 kg; -7.7 lbs)

Additional Analysesi

In-Study

On-Treatment

Time to first occurrence of MACE-5

Hazard ratio = 0.82

95.0% CI: 0.55 to 1.22

Hazard ratio = 0.73

95.0% CI: 0.47 to 1.12

Time to first occurrence of MACE-3

Hazard ratio = 1.12

95.0% CI: 0.64 to 1.96

Hazard ratio = 0.92

95.0% CI: 0.51 to 1.65

iHazard ratio was estimated from Cox proportional hazards model comparing retatrutide (pooled 9 mg and 12 mg) vs. placebo; in-study analysis (pre-specified) includes events which occurred during the study treatment period regardless of adherence to retatrutide or placebo, while on-treatment analysis (not pre-specified) excludes events which occurred more than 35 days after discontinuing retatrutide or placebo.

In TRIUMPH-2, the most common adverse events with retatrutide (4 mg, 9 mg, 12 mg vs. placebo, respectively) were diarrhea (27.4%, 33.5%, 33.6% vs. 13.2%), nausea (13.7%, 20.8%, 28.0% vs. 8.0%), constipation (14.0%, 16.2%, 16.8% vs. 9.4%), decreased appetite (5.8%, 12.3%, 17.1% vs. 4.5%), and vomiting (5.5%, 10.2%, 15.7% vs. 4.2%). In TRIUMPH-3, the most common adverse events with retatrutide (9 mg, 12 mg vs. placebo, respectively) were diarrhea (30.1%, 24.4% vs. 8.7%), nausea (21.7%, 22.4% vs. 5.8%), constipation (18.0%, 15.7% vs. 7.1%), decreased appetite (13.5%, 14.5% vs. 3.0%), and hyperglycemia (3.9%, 3.1% vs. 13.4%). In TRIUMPH-2, the incidence of dysesthesia and urinary tract infections were 4.5%, 5.6%, 7.3% vs. 0.7% and 3.8%, 6.3%, 8.0% vs. 6.6% with retatrutide 4 mg, 9 mg, 12 mg vs. placebo, respectively. In TRIUMPH-3, the incidence of dysesthesia and urinary tract infections were 6.4%, 6.4% vs. 1.3% and 6.1%, 7.0% vs. 5.3% with retatrutide 9 mg, 12 mg vs. placebo, respectively. These events were generally mild to moderate, and the majority resolved during treatment. Discontinuation rates due to adverse events in TRIUMPH-2 were 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) with retatrutide, compared with 4.9% for placebo. Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg) with retatrutide, compared with 4.8% for placebo.

Detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals. Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.

About retatrutide
Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.

About TRIUMPH-2, TRIUMPH-3, and the TRIUMPH clinical trial program
TRIUMPH-2 (NCT05929079) is a Phase 3, 80-week, randomized, double-blind, and placebo-controlled trial under a basket design investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with type 2 diabetes and obesity or overweight. The study randomized 1,152 participants in a 1:1:1:1 ratio to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 4 mg (via steps at 2 mg and 4 mg), 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg). TRIUMPH-2 included a post-treatment follow-up period of four weeks.

TRIUMPH-3 (NCT05882045) is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with severe obesity (Class 2 or Class 3), defined as BMI ≥35 kg/m2, and established cardiovascular disease. The study randomized 1,949 participants in a 1:1:2 ratio to receive retatrutide 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg).

The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.

Endnotes:

The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only). FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com. 

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.  moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back. 

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep

sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time.  Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) [or goto www.zepbound.lilly.com].

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you. 

ZP CON BS 25FEB2026
Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with type 2 diabetes and obesity or overweight and adults with severe obesity and established cardiovascular disease, and the timeline for future readouts, presentations and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:  Niki Biro; [email protected] (Media)
                 Michael Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company
2026-07-24 06:49 8d ago
2026-07-24 00:30 8d ago
2 Top Growth Stocks to Buy Right Now Without Any Hesitation
LLY Eli Lilly & Co
FMP Stock News
Original source text
Some stocks look too attractive to pass up, given their incredibly strong businesses and excellent prospects. In my view, that's the case with Eli Lilly (LLY +1.92%) and Intuitive Surgical (ISRG -2.47%), two healthcare companies. These stocks have delivered excellent returns over the past decade, but neither has peaked yet. Here is why Eli Lilly and Intuitive Surgical are outstanding stocks to buy.

Image source: The Motley Fool.

1. The weight loss leader Obesity is considered an epidemic. It affects a significant percentage of the population, particularly in the U.S., where about 40% of adults are obese, according to the U.S. Centers for Disease Control and Prevention. Obesity is linked to dozens of diseases and costs the U.S. healthcare system tens of billions of dollars every year. For all these reasons, the market for weight management medicines is growing rapidly, and Eli Lilly is currently the leader in this niche.

The company's approved portfolio features Zepbound, a subcutaneous anti-obesity drug, and Foundayo, an oral pill. Both are performing well and helping Eli Lilly grow its revenue much faster than its similarly sized peers in the pharmaceutical industry.

LLY Revenue (Quarterly YoY Growth) data by YCharts

However, Eli Lilly will start facing more competition in this area over the next few years. Not to worry: The company is working hard on next-gen weight-loss therapies, some of which could be even better than its current ones.

Today's Change

(

1.92

%) $

22.27

Current Price

$

1,185.28

Eli Lilly is looking to expand the market, as it did with Foundayo, which is attracting mostly brand-new patients. The company's newer, differentiated medicines might do the same. Eli Lilly's retatrutide, for instance, recently posted an average weight loss of up to 20.8% in patients with type 2 diabetes who were overweight or obese in an 80-week phase 3 study.

That's impressive considering people with diabetes have a harder time losing weight, but retatrutide could be highly effective at helping them do so, largely thanks to the fact that it works by activating three natural hormone pathways (compared to either one or two for most approved therapies) that help people eat less, burn more calories, and better control their blood sugar.

Retatrutide is just one example of Eli Lilly's deep pipeline in this area, which could help it ride the weight-loss tailwind over the next five years. And even beyond this market, Eli Lilly has a large pipeline in other areas, as well as other blockbusters in its approved portfolio. Eli Lilly has been one of the top-performing pharmaceutical giants in recent years, and should remain so. The stock is a no-brainer buy.

2. The sell-off is overdone Intuitive Surgical has faced headwinds in recent years, including increased competition, tariffs, and lower margins on the newest version of its da Vinci surgical system. The company's shares have significantly underperformed the broader market, declining by 33% over the past 12 months. However, Intuitive Surgical's medium-term prospects remain strong, making the current dip a buying opportunity.

Here's why the business is still healthy. Intuitive Surgical's launch of the da Vinci 5 has been hugely successful and presents the company with attractive opportunities, despite its lower margins. This new device lets surgeons feel how much force they're using and runs on a far more powerful computer, advantages which, over time, could enable smarter software, artificial intelligence-assisted surgery, fewer mistakes, and better patient outcomes.

Today's Change

(

-2.47

%) $

-8.40

Current Price

$

332.29

That means additional indications, eventually, and potentially, greater adoption of robotic-assisted surgery (RAS). So, the da Vinci 5's lower margins are worth it once we zoom out and focus on the company's long-term opportunities. It could also help Intuitive Surgical stay ahead of the new competition. The company's da Vinci system already has more than two decades of real-world outcomes to back it up, but it's important to continue innovating, which is what it did with the da Vinci 5.

Further, Intuitive Surgical benefits from a wide moat due to high switching costs, as its expensive devices, which also have a steep learning curve, become far too valuable for hospitals to replace with competitors' devices. That grants the company pricing power, which it might lean on to mitigate the impact of tariffs on its financial results. Intuitive Surgical's stock may remain volatile over the next year or so, but in five years, it could be far above its current levels. Patience will be rewarded.
2026-07-24 06:47 8d ago
2026-07-23 16:13 8d ago
Schwab Declares Quarterly Common Stock Dividend and Declares Preferred Stock Dividends
SCHW Charles Schwab
FMP Stock News
Original source text
WESTLAKE, Texas--(BUSINESS WIRE)--Schwab Declares Quarterly Common Stock Dividend and Declares Preferred Stock Dividends.
2026-07-24 06:45 8d ago
2026-07-23 23:30 8d ago
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
ACN Accenture
FMP Stock News
Original source text
Not every cheap stock is necessarily one worth owning. If you can find the right high-quality, high-yield tickers that are only temporarily beaten down, however, cheap stocks are actually bargains just waiting to be bought.

Here's a rundown of three dirt cheap dividend payers most investors are simply overlooking. That spells opportunity for you.

Novo Nordisk It's not too difficult to figure out why Novo Nordisk (NVO -0.02%) shares are down so much from their 2024 peak. The GLP-1 weight-loss drug race that it helped start has since turned incredibly competitive, so much so that Novo's now losing market share to rival Eli Lilly (LLY +1.92%) (and others) within a business it largely built, forcing price cuts. Investors are also concerned about the limited expansion of Wegovy's label in this environment.

More recently, Novo's decision to file a lawsuit against Lilly (claiming that its top competitor's GLP-1 drug's advertising is misleading) may be valid, but it also suggests a certain degree of concerning desperation. Never even mind the fact that 2026 is now being seen as a "reset" year far sooner than a reset should have been necessary for the company.

Today's Change

(

-0.02

%) $

-0.01

Current Price

$

48.18

However, with the stock now down more than 60% from its mid-2024 high and still within sight of a recently reached five-year low -- and priced at less than 12 times its trailing earnings -- the sellers have arguably overshot their target. They've priced in all of these problems, and then some, without factoring in the fact that Wegovy is still a powerful brand in all of its present and future forms.

That's not the crux of the reason to consider stepping into a position in NVO here and now, however. Rather, the top reason to take a closer look at the beaten-down name at this time is its dividend yield, which currently stands at a little over 3.6% on a forward-looking basis. At the very least, the cash flow supporting these dividend payments will remain intact while the company works through its reset and continues working on the 32 drug trials it's currently got underway, nine of which are now in phase 3.

PepsiCo Novo Nordisk isn't the only attractive dividend name currently dancing with a new 52-week low. Snack food and beverage powerhouse PepsiCo's (PEP -0.52%) shares are in a similar situation. The stock's down 20% from its early February peak, dragging its forward-looking price-to-earnings ratio down to a multiyear low of less than 16, and pumping its forward-looking dividend yield up to 4.4%.

This weakness makes superficial sense. Organic revenue growth remains at a tepid 2.5% pace, bogged down by its North American food business. Cost and health concerns are both contributing factors to this headwind. Meanwhile, last quarter's core operating margin of 16.8% was down 40 basis points from the year-ago comparison, as the company is using price cuts to prop up demand however and whenever it can. Several analysts lowered their price targets on PEP following the release of its Q2 results as well. Investors are understandably nervous.

Image source: Getty Images.

There's nothing PepsiCo is going through now that it hasn't been through and survived before. Although its stock doesn't necessarily recover very quickly from these sorts of setbacks (since the economic underpinnings are also slow-moving), it's now 20% below February's high and down more than 30% from its 2023 peak. This recent weakness is a great opportunity to step into a long-term position in a quality blue chip.

It's a quality blue chip, by the way, that's now raised its dividend for 54 consecutive years. That streak isn't likely to end anytime soon.

Accenture Last but not least, add Ireland-based Accenture Plc (ACN -0.96%) to your list of cheap dividend stocks to buy if you've got $1,000 -- or any other amount -- you're looking to put to work generating income.

It's not a household name, although there's a good chance you or someone in your household benefits from its work. Accenture offers a number of specialized business services, ranging from cybersecurity to supply chain optimization to technology overhauls to risk management. It's serving markets like banks, travel, retail, healthcare, utilities, and more. The company did $69.7 billion in sales last fiscal year, up 7.4% year over year, and is likely to report comparable growth again for the fiscal year ending in August.

Unfortunately, this growth wasn't enough to stave off the 64% setback this stock has suffered since February of last year. You can probably guess why. Investors are fearful that artificial intelligence will eventually be able to replicate much of what this company brings to the table -- and perhaps it will.

Today's Change

(

-0.96

%) $

-1.35

Current Price

$

138.74

As time marches on, however, institutions are learning that AI can't do everything, and too much of what it can do, it doesn't do particularly well. Companies still need plenty of actual people to make experienced judgment calls and apply good common sense that artificial intelligence platforms often just don't have. This is good news for Accenture, and by extension, for its shareholders. It's just not yet evident in the form of a rebound in the stock.

That doesn't mean you have time to wait if you're interested, though. Priced at only 10 times this year's expected per-share profit and with a forward-looking dividend yield of 4.6%, this ticker's apt to fall back into favor sooner rather than later.

Analysts think so, anyway. Their consensus price target of $175.41 is 25% above the stock's present price.
2026-07-24 06:44 8d ago
2026-07-24 06:36 8d ago
Evropské futures kontrakty mírně posilují FIO Stock News
Original source text
Evropské futures kontrakty mírně posilují
2026-07-24 06:44 8d ago
2026-07-24 01:45 8d ago
Strategy Has Now Gone 4 Weeks Without Buying Bitcoin. Should Investors Be Concerned?
MSTR Strategy
FMP Stock News
Original source text
Strategy (MSTR -6.38%) was a huge winner from 2024 through 2025 as it aggressively issued stock and debt to fund Bitcoin purchases. As Bitcoin's price continued to rise, Strategy's massive stockpile soared in value, allowing the company to easily raise more capital, creating a powerful cycle that amassed an enormous Bitcoin stockpile.

Things have changed, though. Bitcoin's price has fallen nearly halfway from its peak last year, and Strategy hasn't been buying the dip lately. Strategy's latest 8-K filing shows that it hasn't purchased any Bitcoin for four consecutive weeks. Instead, it is selling stock to raise funds, increasing its cash reserves to $3.2 billion.

Should investors be concerned about buying Strategy stock amid the company's sudden pivot? Here's what you need to know.

Image source: The Motley Fool.

Fortifying the balance sheet isn't a bad thing Bitcoin is infamously volatile, so a steep decline was probably only a matter of time. It's one thing for an individual investor to buy into a dip, but Strategy is an enormous company with billions of dollars of assets. Opportunistic buying would be nice, but Strategy is focusing on strengthening its balance sheet and preparing for a scenario where Bitcoin continues to decline.

Strategy has 843,775 BTC at an average cost of $75,476 per token. That means that the company is currently sitting on paper losses. It has cash obligations in the form of interest payments on its debt and dividends paid out to preferred shares. Nobody can predict prices, so there's no telling how much lower Bitcoin might go or when it rebounds, or if it ever does.

Holding more cash provides a safety buffer from nightmare situations, such as having to sell at a loss to meet its obligations.

Today's Change

(

-6.38

%) $

-6.38

Current Price

$

93.63

But it does expose a flaw in Strategy's business model Strategy's recent pause in buying Bitcoin makes sense, but it raises some concerns. As a Bitcoin treasury, Strategy could maximize value for shareholders by accumulating Bitcoin at the lowest possible cost basis. If Strategy's playbook of raising money and buying Bitcoin only works when prices go up, that's a potential red flag.

In that case, it's fair to wonder what value Strategy's current business model can generate, other than functioning as a leveraged bet on rising Bitcoin prices. Remember, Strategy primarily issues debt and stock to fund BTC purchases. Issuing stock dilutes existing shareholders, and doesn't work nearly as well at lower share prices because it takes more shares and dilution to raise the same amount of capital.

Strategy is smart to fortify its balance sheet, but a prolonged decline in Bitcoin is still a massive threat to the business. At the end of the day, investors might be better off owning Bitcoin themselves or investing in a spot Bitcoin ETF.
2026-07-24 06:42 8d ago
2026-07-22 19:00 9d ago
Union Pacific and CN Announce Agreement to Improve North American Rail Connectivity
CNI Canadian National Railway
FMP Stock News
Original source text
OMAHA, Neb. & MONTREAL--(BUSINESS WIRE)--Union Pacific Railroad (NYSE: UNP) and CN (NYSE: CNI) today announced the signing of a binding Memorandum of Understanding that will strengthen rail service across North America, improving both railroads' ability to serve customers. The agreement provides Union Pacific with expanded operating rights over CN's Elgin, Joliet & Eastern Railway (EJ&E) corridor through Chicago, while granting CN new rights over Union Pacific's network between Memphis,.
2026-07-24 06:39 8d ago
2026-07-24 01:46 8d ago
SLB Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
SLB Schlumberger
FMP Stock News
Original source text
SLB N.V. (NYSE:SLB) will release its second quarter earnings report before the opening bell on Friday, July 24.

Analysts expect the Houston, Texas-based company to report quarterly earnings of 52 cents per share, down from 74 cents per share in the year-ago period. The consensus estimate for SLB quarterly revenue is $8.68 billion. It reported $8.55 billion last year, according to Benzinga Pro.

On July 14, SLB announced an agreement with Liberty Energy Inc. (NYSE:LBRT) to form a strategic alliance for data center infrastructure and power.

SLB shares fell 0.9% to close at $47.22 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying SLB stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-24 06:34 8d ago
2026-07-24 06:31 8d ago
Intel navyšuje výhled tržeb, Volkswagen letos naopak počítá s jejich poklesem, evropské futures jsou smíšené Patria Stock News
Original source text
Trumpova administrativa zavádí nová cla, v EU jsou z toho překvapeni. Moneta zveřejnila své výsledky a zlepšila výhled, Volkswagen ho naopak zhoršil. Intel začíná čím dál více těžit z datacenter, což se projevuje i na tržbách.

Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.

V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.

Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více
2026-07-24 06:33 8d ago
2026-07-23 07:00 9d ago
Nasdaq Reports Second Quarter 2026 Results; $1.5 Billion in Net Revenue and Historic Milestones Reflect Broad-Based Momentum
NDAQ Nasdaq
FMP Stock News
Original source text
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the second quarter of 2026.

Second quarter 2026 net revenue1 was $1.5 billion, an increase of 15% on both a reported and adjusted2 basis over the second quarter of 2025. Solutions revenue3 grew 17% on both a reported and adjusted basis.
Annualized Recurring Revenue (ARR)3,4 of $3.3 billion increased 11% on a reported basis over the second quarter of 2025, or 12% on an organic basis2. Annualized SaaS revenue increased 12%, or 15% on an organic basis, and represented 38% of ARR.Financial Technology revenue was $539 million, an increase of 16% over the second quarter of 2025, or 15% on an organic basis.Index revenue of $271 million grew 38% or 35% on an adjusted basis over the second quarter of 2025, with $109 billion of net inflows over the trailing twelve months, including $51 billion in the second quarter of 2026.GAAP diluted earnings per share in the second quarter of 2026 was $0.89, an increase of 14% over the second quarter of 2025. Non-GAAP5 diluted earnings per share in the second quarter of 2026 was $1.07, an increase of 25% on both a reported and adjusted basis over the second quarter of 2025.In the second quarter of 2026, the company returned $174 million to shareholders through dividends and $356 million through repurchases of common stock. The company also net repaid $162 million of debt in the quarter. Second Quarter 2026 Highlights

(US$ millions, except per share)2Q26YoY change %Organic2
YoY change %Adjusted2
YoY change %Solutions revenue$1,16017%17%17%Market Services net revenue$34011%11%11%Net revenue$1,50015%16%15%GAAP operating income$71225%  Non-GAAP operating income$85919%20%19%ARR$3,25811%12%12%GAAP diluted EPS$0.8914%  Non-GAAP diluted EPS$1.0725%26%25%
Adena Friedman, Chair and CEO said, “Nasdaq delivered an outstanding second quarter, defined by new records and milestones. We delivered double-digit growth across all three divisions, surpassed $1 trillion in Index ETP AUM, and listed SpaceX, the largest IPO in exchange history.

As the forces reshaping global finance accelerate, from AI and market modernization to the increasingly complex regulatory and risk environment, Nasdaq's role as our clients' trusted transformation partner positions us for sustained leadership. We are confident in our ability to capture the opportunity ahead and deliver durable, long-term value for our clients and shareholders.”

Sarah Youngwood, Executive Vice President and CFO said, “Nasdaq's second quarter results mark another quarter of excellent Solutions revenue growth, expanding operating margins, strong EPS growth, and robust cash flow generation.

Nasdaq’s durable business model and consistent execution support our disciplined capital allocation strategy that returns meaningful capital to shareholders through both dividends and share repurchases while investing in innovations that will sustain our long-term growth trajectory.”

FINANCIAL REVIEW

Second quarter 2026 net revenue was $1.5 billion, reflecting 15% growth on both a reported and adjusted basis versus the prior year period.Solutions revenue was $1.2 billion in the second quarter of 2026, up 17% on both a reported and adjusted basis versus the prior year period, reflecting strong growth across Capital Access Platforms and Financial Technology. Capital Access Platforms revenue growth was 19% year-over-year on a reported basis, or 18% on an adjusted basis. Financial Technology revenue growth was 16% year-over-year, or 15% on an organic basis.ARR was $3.3 billion as of the second quarter of 2026, growing 11% year-over-year on a reported basis, or 12% year-over-year on an organic basis. Financial Technology ARR growth was 16% on both a reported and organic basis, and Capital Access Platforms ARR growth was 8% on both a reported and organic basis. Market Services net revenue was $340 million in the second quarter of 2026, up 11% on both a reported and organic basis versus the prior year period.Second quarter 2026 GAAP operating expenses were $788 million, an increase of 7% versus the prior year quarter and non-GAAP operating expenses were $641 million, up 10% on both a reported and organic basis versus the prior year quarter. The increases were primarily driven by higher compensation and benefits costs from our strong revenue execution, increased marketing and advertising costs due to a strengthening IPO environment, and increased investments in technology to drive long-term growth. On a GAAP basis, the increase was partially offset by lower merger and strategic initiatives expense.Cash flow from operations was $711 million in the second quarter, enabling the return of capital through Nasdaq’s efficient capital allocation framework. In the second quarter of 2026, the company returned $174 million to shareholders through dividends and $356 million through repurchases of common stock. As of June 30, 2026, there was $2.5 billion remaining under the board authorized share repurchase program. 2026 EXPENSE AND TAX GUIDANCE UPDATE6

The company is updating its 2026 non-GAAP operating expense guidance to a range of $2.530 billion to $2.570 billion. The company is maintaining its 2026 non-GAAP tax rate guidance in the range of 22.5% to 24.5%. STRATEGIC AND BUSINESS UPDATES

Financial Technology delivered double-digit revenue growth in each subdivision for the second consecutive quarter as the One Nasdaq strategy continues to unlock broad-based growth. In the second quarter, FinTech revenue increased 16% compared to the prior year period, or 15% on an organic basis, with 16% organic ARR growth. FinTech signed 58 new clients, 7 cross-sells, and 107 upsells in the quarter, with cross-sells remaining over 15% of the sales pipeline. Financial Crime Management Technology maintained strong momentum across both SMBs and enterprise clients while advancing AI-driven innovation in financial crime detection. During the quarter, Nasdaq Verafin signed 47 new small-and-medium bank (SMB) clients and 6 enterprise deals, including 2 cross-sells. Including signings early in the third quarter, Verafin has completed 11 enterprise signings year-to-date, surpassing the total signed in all of 2025. Nasdaq Verafin’s Agentic Workforce continued to gain traction, with 750 clients now leveraging the platform. The business introduced the next two agentic workers, the Agentic AML Analyst and the Agentic Fraud Analyst, while continuing to expand its innovation pipeline. Nasdaq Verafin enhanced the value of its gold-standard consortium data, surpassing $13 trillion in combined assets across more than 2,800 financial institutions.Regulatory Technology delivered strong performance across Surveillance and AxiomSL, driven by accelerating demand for Always-On infrastructure and regulatory modernization. The subdivision signed 9 new clients, including 2 cross-sells, and 63 upsells in the second quarter. Surveillance added 9 new clients, including 2 cross-sells, and 39 upsells with wins across geographies and client segments, including a new regulator win in Africa, and an upsell with a global broker-dealer. Early in the third quarter, Surveillance signed a notable first win for its AI-powered Calibration Copilot with a Tier 1 client. AxiomSL signed 24 upsells in the quarter with several client expansions that demonstrate the breadth of demand for AxiomSL's regulatory solutions, including with a domestic systemically important Australian bank and with a U.S. bank navigating heightened regulatory requirements following an acquisition.Capital Markets Technology delivered quarterly organic revenue growth of 14% and strong 17% organic ARR growth, reflecting the growing scale and reach of its global platform. The subdivision signed 7 new clients, including 3 cross-sells, and 42 upsells in the second quarter. Trade Management Services benefitted from strong demand for data center services and pricing. Calypso signed 3 new clients, including 1 cross-sell, and 31 upsells and is now available in more than 70 countries. Calypso expanded its global presence by signing a deal with the Georgian Financial Markets Treasury Association (GFTMA) to modernize the country’s treasury and financial markets infrastructure. The GFTMA deal includes a group of 5 of the country’s largest banks, which will adopt Calypso under a shared common infrastructure model. Market Technology continued to drive market modernization with the next-generation Eqlipse platform, signing 2 new digital marketplaces and 2 new clients on the Intelligence Platform. Index ETP assets under management (AUM) exceeded $1 trillion for the first time and achieved new net inflows records. Net inflows reached new all-time highs with $51 billion in the second quarter and $109 billion over the last twelve months. ETP AUM surpassed $1 trillion for the first time, with end-of-period ETP AUM of $1.114 trillion and average ETP AUM of $1.014 trillion. Nasdaq launched 34 new Index products in the second quarter, including 17 international products and 11 products in the institutional annuity space. Nasdaq expanded investor access to the Nasdaq-100 with the recent launch of BlackRock’s IQQ and State Street’s QNDX ETFs in the U.S.Listings set a quarterly record for total proceeds raised, headlined by the listing of SpaceX, the largest IPO in exchange history with an $86 billion raise. Nasdaq welcomed 7 of the top 10 largest operating company IPOs listed in the quarter, including Cerebras, the largest semiconductor IPO of all time, Quantinuum, the largest pure-play quantum IPO of all time, and Parabilis Medicines, the largest biotechnology IPO of all time. Nasdaq achieved a 74% win rate7 of new operating company listings. The momentum carried into the third quarter with the listing of SK hynix, the largest American Depositary Receipt (ADR) listing in U.S. capital markets history, underscoring the continued strength of the franchise.Market Services delivered records across quarterly net revenues and U.S. equity options volumes, supported by record industry volumes. In the second quarter, the business successfully facilitated the execution and trading of the SpaceX IPO. Nasdaq’s Closing Cross achieved new records across two landmark market events: during the Russell reconstitution, it executed 4.6 billion shares in 1.6 seconds representing a record $334 billion in notional value, and during the June Triple Witch, it executed a record $296 billion in notional value. Product innovation continued to drive incremental growth, with Index options revenue more than doubling year-over-year for the fourth consecutive quarter. Nasdaq received SEC approval to list event options tied to the Nasdaq-100 with an expected launch in the fourth quarter.Nasdaq advanced Always-On markets as Calypso supported proof of concept tokenized collateral trades on the Canton Network. Calypso, a leading platform managing the entire trade lifecycle, is powering the transition to hybrid tokenized and fiat infrastructure. Early in the third quarter, two of the world’s leading asset managers successfully completed tokenized collateral trades on the Canton Network, transmitting tokenized money market funds through Calypso. This milestone marks a significant step in the shift towards integrating tokenized and fiat infrastructure and reflects Nasdaq’s unique position as the trusted technology for next-generation markets.Nasdaq continued to optimize its portfolio early in the third quarter, entering into agreements to sell Nasdaq Fund Secondaries to Nasdaq Private Market and to acquire Dasseti. After the close of the Nasdaq Fund Secondaries transaction, Nasdaq will continue to hold an ownership stake in and remain a strategic partner of Nasdaq Private Market. Dasseti provides an AI-powered due diligence platform for institutional asset managers and allocators across public and private markets and will be integrated into eVestment’s leading institutional intelligence platform. Both transactions remain subject to customary closing conditions. ____________
1 Represents revenue less transaction-based expenses.
2 Organic change is calculated by removing the impacts of changes in foreign exchange rates, and acquisitions and divestitures during one-year period post transaction.   Adjusted period over period change reflects the organic change, excluding the impact of a one-time revenue benefit in the second quarter of 2026 in our Index business due to a contract modification.
3 Solutions revenue and Annualized Recurring Revenue (ARR) constitutes revenue and ARR from our Capital Access Platforms and Financial Technology segments as well as revenue and ARR from our Solovis business which was sold in October 2025. Solovis revenues and ARR were previously included in our Capital Access Platforms segment, and have been reclassified into “Other” for all prior periods presented.
4 ARR for a given period is the current annualized value derived from subscription contracts with a defined contract value. This excludes contracts that are not recurring, are one-time in nature or where the contract value fluctuates based on defined metrics. For AxiomSL and Calypso recurring revenue contracts, the amount included in ARR is consistent with the amount that we invoice the customer during the current period. Additionally, for AxiomSL and Calypso recurring revenue contracts that include annual values that increase over time, we include in ARR only the annualized value of components of the contract that are considered active as of the date of the ARR calculation. We do not include the future committed increases in the contract value as of the date of the ARR calculation. ACV Bookings for our Financial Technology segment excluding Financial Crime Management Technology refers to the maximum annualized committed contract value at the time of signature, excluding one-time fees and not accounting for initial discounts. For Financial Crime Management Technology, ACV bookings is calculated by averaging the total contract value over the contract term, including fixed increases. ARR and ACV are supplemental metrics to help evaluate the performance of the business. These measures are not a replacement for, and should be viewed independently of, U.S. GAAP revenue and deferred revenue as they are performance metrics, and are not intended to be combined with any of these items. ARR and ACV are not a forecast, and the active contracts at the end of a reporting period used in calculating these measures may or may not be extended or renewed by our customers. There is no U.S. GAAP measure comparable to ARR or ACV. As these metrics do not have any standardized definition they may not be comparable to similarly titled measures presented by other companies and should be viewed independently of revenue and deferred revenue and are not intended to be combined with or to replace either of those items.
5 Refer to our reconciliations of U.S. GAAP to non-GAAP metrics and organic and adjusted impacts, included in the attached schedules.
6 U.S. GAAP operating expense and tax rate guidance are not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.
7 Listings win rate includes eligible U.S. operating companies, direct listings, and SPAC business combinations.

ABOUT NASDAQ

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

NON-GAAP INFORMATION

In addition to disclosing results determined in accordance with U.S. GAAP, Nasdaq also discloses certain non-GAAP results of operations, including, but not limited to, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP operating income, and non-GAAP operating expenses, that include certain adjustments or exclude certain charges and gains that are described in the reconciliation tables of U.S. GAAP to non-GAAP information provided at the end of this release. Management uses this non-GAAP information internally, along with U.S. GAAP information, in evaluating our performance and in making financial and operational decisions. We believe our presentation of these measures provides investors with greater transparency and supplemental data relating to our financial condition and results of operations. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.

These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.

We understand that analysts and investors regularly rely on non-GAAP financial measures, such as those noted above, to assess operating performance. We use these measures because they highlight trends more clearly in our business that may not otherwise be apparent when relying solely on U.S. GAAP financial measures, since these measures eliminate from our results specific financial items that have less bearing on our ongoing operating performance.

Foreign exchange impact: In countries with currencies other than the U.S. dollar, revenue and expenses are translated using monthly average exchange rates. Certain discussions in this release isolate the impact of year-over-year foreign currency fluctuations to better measure the comparability of operating results between periods. Operating results excluding the impact of foreign currency fluctuations are calculated by translating the current period’s results by the prior period’s exchange rates.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to (i) projections relating to our future financial results, total shareholder returns, growth, dividend program, trading volumes, products and services, ability to transition to new business models, taxes and achievement of synergy targets, (ii) statements about the closing or implementation dates and benefits of certain acquisitions, divestitures and other strategic, restructuring, technology, de-leveraging and capital allocation initiatives, (iii) statements about our integrations of our recent acquisitions, (iv) statements relating to any litigation or regulatory or government investigation or action to which we are or could become a party, and (v) other statements that are not historical facts. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These factors include, but are not limited to, Nasdaq’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, geopolitical instability, government and industry regulation, interest rate risk, and U.S. and global competition. Further information on these and other factors are detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q, which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

WEBSITE DISCLOSURE

Nasdaq intends to use its website, ir.nasdaq.com, as a means for disclosing material non-public information and for complying with SEC Regulation FD and other disclosure obligations.

Media Relations Contact:
David Lurie
+1.914.538.0533
[email protected]

Investor Relations Contact:
Ato Garrett
+1.212.401.8737
[email protected]

-NDAQF-

Nasdaq, Inc.Condensed Consolidated Statements of Income(in millions, except per share amounts)(unaudited)       Three Months Ended Six Months Ended June 30, June 30, June 30, June 30,  2026   2025   2026   2025          Revenues:       Capital Access Platforms$621  $520  $1,186  $1,028 Financial Technology 539   464   1,057   896 Market Services 1,372   1,101   2,419   2,240 Other Revenues —   16   8   32  Total revenues 2,532   2,101   4,670   4,196 Transaction-based expenses:       Transaction rebates (712)  (640)  (1,436)  (1,224)Brokerage, clearance and exchange fees (320)  (155)  (326)  (429)Revenues less transaction-based expenses 1,500   1,306   2,908   2,543         Operating Expenses:       Compensation and benefits 383   352   739   681 Professional and contract services 42   39   82   75 Technology and communication infrastructure 88   79   171   156 Occupancy 35   30   68   58 General, administrative and other 23   23   52   29 Marketing and advertising 24   14   44   28 Depreciation and amortization 165   158   331   313 Regulatory 9   14   19   29 Merger and strategic initiatives 5   20   9   44 Restructuring charges 14   9   24   15  Total operating expenses 788   738   1,539   1,428 Operating income 712   568   1,369   1,115 Interest income 8   12   13   24 Interest expense (86)  (95)  (172)  (192)Net gain on divestitures —   39   89   39 Other income (losses) (2)  1   (15)  — Net income from unconsolidated investees 21   23   47   50 Income before income taxes 653   548   1,331   1,036 Income tax provision 146   96   305   190 Net income$507  $452  $1,026  $846 Net loss attributable to noncontrolling interests —   —   —   1 Net income attributable to Nasdaq$507  $452  $1,026  $847         Per share information:       Basic earnings per share$0.90  $0.79  $1.81  $1.47 Diluted earnings per share$0.89  $0.78  $1.80  $1.46 Cash dividends declared per common share$0.31  $0.27  $0.58  $0.51         Weighted-average common shares outstanding       for earnings per share:       Basic 564.2   574.1   565.5   574.6 Diluted 567.8   579.0   569.7   579.5  Nasdaq, Inc.Revenue Detail(in millions)(unaudited)       Three Months Ended Six Months Ended June 30, June 30, June 30, June 30,  2026   2025   2026   2025         CAPITAL ACCESS PLATFORMS       Data and Listing Services$217  $198  $431  $391 Index 271   196   491   388 Workflow and Insights 133   126   264   249 Total Capital Access Platforms revenues 621   520   1,186   1,028         FINANCIAL TECHNOLOGY       Financial Crime Management Technology 98   81   191   157 Regulatory Technology 120   104   238   206 Capital Markets Technology 321   279   628   533 Total Financial Technology revenues 539   464   1,057   896         MARKET SERVICES       Market Services 1,372   1,101   2,419   2,240 Transaction-based expenses:       Transaction rebates (712)  (640)  (1,436)  (1,224)Brokerage, clearance and exchange fees (320)  (155)  (326)  (429)Total Market Services revenues, net 340   306   657   587         OTHER REVENUES —   16   8   32         REVENUES LESS TRANSACTION-BASED EXPENSES$1,500  $1,306  $2,908  $2,543  Nasdaq, Inc.Condensed Consolidated Balance Sheets(in millions)       June 30, December 31,   2026   2025 Assets (unaudited)  Current assets:    Cash and cash equivalents $520  $604 Restricted cash and cash equivalents  26   210 Default funds and margin deposits  2,323   5,842 Financial investments  198   28 Receivables, net  1,182   943 Other current assets  284   376 Total current assets  4,533   8,003 Property and equipment, net  767   728 Goodwill  14,245   14,371 Intangible assets, net  6,223   6,511 Operating lease assets  481   447 Other non-current assets  1,092   993 Total assets $27,341  $31,053      Liabilities    Current liabilities:    Accounts payable and accrued expenses $252  $280 Section 31 fees payable to SEC  313   — Accrued personnel costs  243   364 Deferred revenue  931   785 Other current liabilities  174   259 Default funds and margin deposits  2,323   5,842 Short-term debt  269   431 Total current liabilities  4,505   7,961 Long-term debt  8,492   8,573 Deferred tax liabilities, net  1,616   1,584 Operating lease liabilities  482   462 Other non-current liabilities  253   241 Total liabilities  15,348   18,821      Commitments and contingencies    Equity    Nasdaq stockholders' equity:    Common stock  6   6 Additional paid-in capital  4,353   5,122 Common stock in treasury, at cost  (784)  (716)Accumulated other comprehensive loss  (1,874)  (1,773)Retained earnings  10,287   9,588 Total Nasdaq stockholders' equity  11,988   12,227 Noncontrolling interests  5   5 Total equity  11,993   12,232 Total liabilities and equity $27,341  $31,053  Nasdaq, Inc.Reconciliation of U.S. GAAP to Non-GAAP Net Income and Diluted Earnings Per Share(in millions, except per share amounts)(unaudited)             Three Months Ended Six Months Ended   June 30, June 30, June 30, June 30,    2026   2025   2026   2025           U.S. GAAP net income $507  $452  $1,026  $847 Non-GAAP adjustments:        Amortization expense of acquired intangible assets1  121   122   243   243 Merger and strategic initiatives expense2  5   20   9   44 Restructuring charges3  14   9   24   15 Gain from extinguishment of debt4  —   —   —   (19)Legal and regulatory matters5  6   1   12   4 Net gain on divestitures6  —   (39)  (89)  (39)Net income from unconsolidated investees7  (21)  (23)  (47)  (50)Other losses8  6   1   20   1 Total non-GAAP adjustments  131   91   172   199 Non-GAAP adjustment to the income tax provision9  (33)  (24)  (44)  (52)Other tax adjustments10  —   (27)  —   (45)Total non-GAAP adjustments, net of tax  98   40   128   102 Non-GAAP net income $605  $492  $1,154  $949           U.S. GAAP diluted earnings per share $0.89  $0.78  $1.80  $1.46 Total adjustments from non-GAAP net income above  0.18   0.07   0.23   0.18 Non-GAAP diluted earnings per share $1.07  $0.85  $2.03  $1.64           Weighted-average diluted common shares outstanding for earnings per share:  567.8   579.0   569.7   579.5  Nasdaq, Inc.Reconciliation of U.S. GAAP to Non-GAAP Operating Income and Operating Margin(in millions)(unaudited)           Three Months Ended Six Months Ended   June 30, June 30, June 30, June 30,    2026   2025   2026   2025 U.S. GAAP operating income $712  $568  $1,369  $1,115 Non-GAAP adjustments:        Amortization expense of acquired intangible assets1  121   122   243   243 Merger and strategic initiatives expense2  5   20   9   44 Restructuring charges3  14   9   24   15 Gain from extinguishment of debt4  —   —   —   (19)Legal and regulatory matters5  6   1   12   4 Other losses  1   1   1   1 Total non-GAAP adjustments  147   153   289   288 Non-GAAP operating income $859  $721  $1,658  $1,403          Revenues less transaction-based expenses $1,500  $1,306  $2,908  $2,543           U.S. GAAP operating margin11  47%  44%  47%  44%          Non-GAAP operating margin12  57%  55%  57%  55%          Note: The percentages are calculated based on exact dollars, and therefore may not recalculate exactly using rounded numbers as presented in US$ millions.           Nasdaq, Inc.Reconciliation of U.S. GAAP to Non-GAAP Operating Expenses(in millions)(unaudited)           Three Months Ended Six Months Ended   June 30, June 30, June 30, June 30,    2026   2025   2026   2025           U.S. GAAP operating expenses $788  $738  $1,539  $1,428 Non-GAAP adjustments:        Amortization expense of acquired intangible assets1  (121)  (122)  (243)  (243)Merger and strategic initiatives expense2  (5)  (20)  (9)  (44)Restructuring charges3  (14)  (9)  (24)  (15)Gain on extinguishment of debt4  —   —   —   19 Legal and regulatory matters5  (6)  (1)  (12)  (4)Other losses  (1)  (1)  (1)  (1)Total non-GAAP adjustments  (147)  (153)  (289)  (288)Non-GAAP operating expenses $641  $585  $1,250  $1,140            Nasdaq, Inc.Footnotes to Press ReleaseFinancial Tables 1We amortize intangible assets acquired in connection with various acquisitions. Intangible asset amortization expense can vary from period to period due to episodic acquisitions completed, rather than from our ongoing business operations.2We have pursued various strategic initiatives and completed acquisitions and divestitures in recent years that have resulted in expenses which would not have otherwise been incurred. These expenses generally include integration costs, as well as legal, due diligence and other third-party transaction costs. The frequency and the amount of such expenses vary significantly based on the size, timing and complexity of the transaction. For the three and six months ended June 30, 2026, these costs included amounts associated with various strategic initiative costs. For the three and six months ended June 30, 2025, these costs primarily included amounts associated with the transfer of open positions in our Nordic power futures business, Adenza integration costs and other strategic initiative costs.3In the fourth quarter of 2023, following the closing of the Adenza acquisition, our management approved, committed to and initiated a restructuring program, “Adenza Restructuring” to optimize our efficiencies as a combined organization. We initiated the program upon the acquisition of Adenza and further expanded the program in the fourth quarter of 2024 following the achievement of our initial targets. We have incurred costs principally related to employee-related costs, contract terminations, asset impairments and other related costs and expect to incur additional costs in these areas in an effort to accelerate efficiencies through location strategy and enhanced AI capabilities. Actions taken as part of this program were completed as of December 31, 2025, and all costs have been incurred as of June 30, 2026.4For the six months ended June 30, 2025, we recorded a gain on the extinguishment of debt. This gain is recorded in general, administrative and other expense in our Condensed Consolidated Statements of Income.5For the three and six months ended June 30, 2026 and 2025, this includes accruals relating to certain legal matters, which are recorded in professional and contract services in our Condensed Consolidated Statements of Income.6For the six months ended June 30, 2026, this primarily includes the recognition of an incremental gain on the divestiture of our Nordic power futures business, net of costs to sell. For the three and six months ended June 30, 2025, this includes gains on divestitures of our Nordic power futures business and our Nasdaq Risk Modelling for Catastrophes business.7We exclude our share of the earnings and losses of our equity method investments. This provides a more meaningful analysis of Nasdaq’s ongoing operating performance or comparisons in Nasdaq’s performance between periods.8For the three and six months ended June 30, 2026 and 2025, other items primarily include net gains and losses from strategic investments entered into through our corporate venture program. For the three and six months ended June 30, 2026, this also includes intangible asset impairments of customer relationships and licenses relating to the wind-down of our Nordic power futures business. The net effect of these items is included in other income (losses) in our Condensed Consolidated Statements of Income.9For the three and six months ended June 30, 2026 and 2025, the non-GAAP adjustment to the income tax provision primarily includes the tax impact of each non-GAAP adjustment.10For the three and six months ended June 30, 2025, other tax adjustments reflect a tax benefit related to payments made to certain former Adenza employees. For the six months ended June 30, 2025, this also reflects the release of the prior years' reserves following a favorable audit settlement.11U.S. GAAP operating margin equals U.S. GAAP operating income divided by revenues less transaction-based expenses.12Non-GAAP operating margin equals non-GAAP operating income divided by revenues less transaction-based expenses.
Nasdaq, Inc.Reconciliation of Organic and Adjusted Impacts (in millions, except per share amounts)(unaudited)                                   Three Months
Ended
June 30,  Total Variance FX/Divestitures/
Acquisition
impact Organic Variance1 Adjustment Adjusted
Variance1 2026
2025
 $% $% $% $ $%Capital Access Platforms                Data and Listing Services$217$198 $19 10% $1 —% $189% $— $189%Index 271 196  75 38%  — —%  7538%  6  6935%Workflow and Insights 133 126  7 5%  1 —%  65%  —  65%Total Capital Access Platforms revenues 621 520  101 19%  2 —%  9919%  6  9318%                 Financial Technology                Financial Crime Management Technology 98 81  17 22%  — —%  1722%  —  1722%Regulatory Technology 120 104  16 15%  2 —%  1413%  —  1413%Capital Markets Technology 321 279  42 15%  2 —%  4014%  —  4014%Total Financial Technology revenues 539 464  75 16%  4 —%  7115%  —  7115%                 Market Services net revenues 340 306  34 11%  1 —%  3311%  —  3311%                 Other revenues — 16  (16)(100)%  (16)(100)%  ——%  —  ——%                 Revenues less transaction-based expenses$1,500$1,306 $194 15% $(9)(1)% $20316% $6 $19715%                 Solutions revenue 2$1,160$991 $169 17% $(1)(1)% $17017% $6 $16417%                 Non-GAAP Operating Expenses$641$585 $56 10% $(4)(1)% $6010% $— $6010%                 Non-GAAP Operating Income$859$721 $138 19% $(5)(1)% $14320% $6 $13719%                 Non-GAAP diluted earnings per share$1.07$0.85 $0.22 25% $— —% $0.2226% $0.01 $0.2125%                 Note: The percentages are calculated based on exact dollars, and therefore may not recalculate exactly using rounded numbers as presented in US$ millions. The sum of the percentage changes may not tie to the percentage change in total variance due to rounding.                 1 Adjusted and organic variance is calculated by removing the impacts of changes in foreign exchange rates, an acquisition, and divestitures. Adjusted variance also excludes a one-time revenue benefit in our Index business in the second quarter of 2026.                 2 Total Solutions revenues includes Capital Access Platforms and Financial Technology revenues as well as $7 million of Other revenue in the second quarter of 2025, related to the sale of the Solovis business, which was sold in the fourth quarter of 2025. Nasdaq, Inc.Key Drivers Detail(unaudited)                    Three Months
Ended Six Months
Ended  June 30, June 30,   2026   2025   2026   2025 Capital Access Platforms        Annualized recurring revenues (in millions) 1$1,388  $1,286  $1,388  $1,286  Initial public offerings        The Nasdaq Stock Market 68   79   131   142  Nasdaq operating company IPOs 26   38   41   83  SPACs 42   41   90   59  Exchanges that comprise Nasdaq Nordic and Nasdaq Baltic 11   6   13   10  Total new listings        The Nasdaq Stock Market 188   194   364   364  Exchanges that comprise Nasdaq Nordic and Nasdaq Baltic 2 15   6   20   15  Number of listed companies        The Nasdaq Stock Market 3 4,659   4,238   4,659   4,238  Exchanges that comprise Nasdaq Nordic and Nasdaq Baltic 4 1,109   1,148   1,109   1,148  Index        Number of licensed exchange traded products 481   422   481   422  Period end ETP assets under management (AUM) tracking Nasdaq indexes (in billions)$1,114  $745  $1,114  $745  Total average ETP AUM tracking Nasdaq indexes (in billions)$1,014  $663  $946  $662  TTM 5 net inflows ETP AUM tracking Nasdaq indexes (in billions)$109  $88  $109  $88  TTM 5 net appreciation ETP AUM tracking Nasdaq indexes (in billions)$260  $88  $260  $88          Financial Technology        Annualized recurring revenues (in millions) 1        Financial Crime Management Technology$359  $308  $359  $308  Regulatory Technology 428   376   428   376  Capital Markets Technology 1,083   932   1,083   932  Total Financial Technology$1,870  $1,616  $1,870  $1,616          Market Services        Equity Derivative Trading and Clearing        U.S. equity options        Total industry average daily volume (in millions) 66.5   52.5   64.6   53.0  Nasdaq PHLX matched market share 11.2%  9.6%  11.8%  9.4% The Nasdaq Options Market matched market share 2.6%  4.3%  2.6%  4.7% Nasdaq Texas Options matched market share (formerly Nasdaq BX) 1.3%  1.7%  1.3%  1.7% Nasdaq ISE Options matched market share 6.6%  6.6%  6.4%  6.7% Nasdaq GEMX Options matched market share 3.4%  4.4%  3.4%  4.0% Nasdaq MRX Options matched market share 4.0%  2.8%  4.1%  2.8% Total matched market share executed on Nasdaq's exchanges 29.1%  29.4%  29.6%  29.3% Nasdaq Nordic and Nasdaq Baltic options and futures        Total average daily volume of options and futures contracts 221,789   223,450   235,945   240,133          Cash Equity Trading          Total U.S.-listed securities          Total industry average daily share volume (in billions) 20.2   18.4   20.1   17.1 Matched share volume (in billions) 184.5   158.4   368.2   295.5 The Nasdaq Stock Market matched market share 14.3%  13.5%  14.5%  13.8%Nasdaq Texas matched market share (formerly Nasdaq BX) 0.3%  0.3%  0.3%  0.3%Nasdaq PSX matched market share 0.1%  0.1%  0.1%  0.1%Total matched market share executed on Nasdaq's exchanges 14.7%  13.9%  14.9%  14.2%Market share reported to the FINRA/Nasdaq Trade Reporting Facility 46.4%  47.7%  46.0%  47.9%Total market share 6 61.1%  61.6%  60.9%  62.1%Nasdaq Nordic and Nasdaq Baltic securities           Average daily number of equity trades executed on Nasdaq's exchanges 747,410   804,121   773,062  796,426 Total average daily value of shares traded (in billions)$6.2  $5.7  $6.5 $5.5 Total market share executed on Nasdaq's exchanges 7 74.5% 71.9%  74.4% 71.2%                  1Annualized Recurring Revenue (ARR) for a given period is the current annualized value derived from subscription contracts with a defined contract value. This excludes contracts that are not recurring, are one-time in nature, or where the contract value fluctuates based on defined metrics. ARR is currently one of our key performance metrics to assess the health and trajectory of our recurring business. ARR does not have any standardized definition and is therefore unlikely to be comparable to similarly titled measures presented by other companies. ARR should be viewed independently of revenue and deferred revenue and is not intended to be combined with or to replace either of those items. For AxiomSL and Calypso recurring revenue contracts, the amount included in ARR is consistent with the amount that we invoice the customer during the current period. Additionally, for AxiomSL and Calypso recurring revenue contracts that include annual values that increase over time, we include in ARR only the annualized value of components of the contract that are considered active as of the date of the ARR calculation. We do not include the future committed increases in the contract value as of the date of the ARR calculation. ARR is not a forecast and the active contracts at the end of a reporting period used in calculating ARR may or may not be extended or renewed by our customers.2New listings include IPOs and represent companies listed on the Nasdaq Nordic and Nasdaq Baltic exchanges and companies on the alternative markets of Nasdaq First North.3Number of total listings on The Nasdaq Stock Market for the three and six months ended June 30, 2026 and 2025 included 1,243 and 914 ETPs, respectively.4Represents companies listed on the Nasdaq Nordic and Nasdaq Baltic exchanges and companies on the alternative markets of Nasdaq First North.5Trailing twelve months.6Includes transactions executed on The Nasdaq Stock Market's, Nasdaq Texas's (formerly Nasdaq BX) and Nasdaq PSX's systems plus trades reported through the Financial Industry Regulatory Authority/Nasdaq Trade Reporting Facility.7European cash equities markets include cash equities exchanges of Sweden, Denmark, Finland, and Iceland. Minor adjustments to prior periods reflect data from a new consolidated data provider that accurately captures all primary trading venues and Multilateral Trading Facilities, or MTFs.  
2026-07-24 06:33 8d ago
2026-07-23 07:01 9d ago
Nasdaq Announces Quarterly Dividend of $0.31 Per Share
NDAQ Nasdaq
FMP Stock News
Original source text
July 23, 2026 07:01 ET  | Source: Nasdaq, Inc.

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.31 per share on the company's outstanding common stock. The dividend is payable on September 25, 2026 to shareholders of record at the close of business on September 11, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at  www.nasdaq.com.

Cautionary Note Regarding Forward-Looking Statements
Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance, and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to, information regarding our dividend program and future payment obligations. Forward-looking statements involve a number of risks, uncertainties, or other factors beyond Nasdaq’s control. These factors include, but are not limited to, Nasdaq’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Relations Contact:
David Lurie
+1.914.538.0533
[email protected]

Investor Relations Contact:
Ato Garrett
+1.212.401.8737
[email protected]

-NDAQF-
2026-07-24 06:29 8d ago
2026-07-23 08:00 9d ago
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Agilent Technologies
FMP Stock News
Original source text
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.
2026-07-24 06:16 8d ago
2026-07-23 06:30 9d ago
Snap-on Announces Second Quarter 2026 Results
SNA Snap-On
FMP Stock News
Original source text
KENOSHA, Wis.--(BUSINESS WIRE)--Snap-on Incorporated today announced 2026 second quarter results, including net sales of $1,235.1 million and diluted EPS of $4.96 per share.
2026-07-24 06:14 8d ago
2026-07-24 06:02 8d ago
Očekávané události: Index nákupních manažerů PMI (eurozóna, Německo, USA), prodeje nových domů (USA) FIO Stock News
Original source text
24.7.2026 08:02

Česká republika:

09:00 Index spotřebitelské důvěry (červenec): očekávání trhu: 107, předchozí hodnota: 106,5

09:00 Spotřebitelská a podnikatelská důvěra (červenec): očekávání trhu: 101,5, předchozí hodnota: 101

09:00 Podnikatelská důvěra (červenec): očekávání trhu: 99,8, předchozí hodnota: 99,8

Německo:

08:00 Spotřebitelská důvěra GfK (srpen): očekávání trhu: -28,5, předchozí hodnota: -29,2

09:30 Index nákupních manažerů PMI ve výrobě (S&P Global / BME) (červenec - předběžný): očekávání trhu: 50,5, předchozí hodnota: 50,3

09:30 Index nákupních manažerů PMI ve službách (S&P Global) (červenec - předběžný): očekávání trhu: 49, předchozí hodnota: 48,6

09:30 Index nákupních manažerů PMI - kompozitní (S&P Global) (červenec - předběžný): očekávání trhu: 49,7, předchozí hodnota: 49,5

Eurozóna:

10:00 Index nákupních manažerů PMI ve výrobě (S&P Global) (červenec - předběžný): očekávání trhu: 51,5, předchozí hodnota: 51,4

10:00 Index nákupních manažerů PMI ve službách (S&P Global) (červenec - předběžný): očekávání trhu: 49,8, předchozí hodnota: 49,4

10:00 Index nákupních manažerů PMI - kompozitní (S&P Global) (červenec - předběžný): očekávání trhu: 50,2, předchozí hodnota: 50

USA:

15:45 Index nákupních manažerů PMI ve výrobě (S&P Global) (červenec - předběžný): očekávání trhu: 54,4, předchozí hodnota: 53,9

15:45 Index nákupních manažerů PMI ve službách (S&P Global) (červenec - předběžný): očekávání trhu: 51,5, předchozí hodnota: 51,2

15:45 Index nákupních manažerů PMI - kompozitní (S&P Global) (červenec - předběžný): očekávání trhu: 51,8, předchozí hodnota: 51,9

16:00 Prodeje nových domů (červen): očekávání trhu: 606 tis., předchozí hodnota: 580 tis.

16:00 Prodeje nových domů (m-m) (červen): očekávání trhu: 4,7 %, předchozí hodnota: -7,3 %Zdroj: Bloomberg

Marek Krejčiřík
Fio banka, a.s.
Prohlášení
2026-07-24 06:14 8d ago
2026-07-23 07:50 9d ago
United Bankshares, Inc. Announces Record Earnings for the Second Quarter of 2026
UBSI United Bankshares
FMP Stock News
Original source text
WASHINGTON & CHARLESTON, W.Va.--(BUSINESS WIRE)--United Bankshares, Inc. Announces Record Earnings for the Second Quarter of 2026.
2026-07-24 06:14 8d ago
2026-07-23 16:17 8d ago
Brown-Forman Stockholders Elect Directors
BF-A Brown-Forman Corporation
FMP Stock News
Original source text
LOUISVILLE, Ky.--(BUSINESS WIRE)--Brown‑Forman Corporation (NYSE: BFA, BFB) stockholders convened today for their annual meeting, where they elected the slate of directors recommended by the Board of Directors, as submitted in the company's 2026 Proxy Statement. The stockholders also approved the compensation of the company's named executive officers on a non-binding advisory basis and ratified the selection of Ernst & Young LLP as Brown-Forman's independent registered public accounting firm for fiscal 2027.
2026-07-24 06:09 8d ago
2026-07-24 00:43 8d ago
Silgan Holdings: Cheap, But Not Not Compelling Enough To Unwrap An Upgrade
SLGN Silgan Holdings
FMP Stock News
Original source text
37.63K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2026-07-24 06:06 8d ago
2026-07-24 01:56 8d ago
Bloom Energy Q2 Preview: What I Need To See To Stay Bullish
BE Bloom Energy
FMP Stock News
Original source text
HomeEarnings AnalysisIndustrial 

SummaryBloom Energy is upgraded from Hold to Buy, driven by its tech moat in solid oxide fuel cells and accelerating growth.BE’s Q1 revenue surged 130% YoY, with the product segment up 208% and strong margin expansion across all segments.I expect Q2 catalysts: higher segment margins, another large hyperscaler deal, sustained positive operating cash flow, and continued manufacturing cost reductions.Despite premium valuation, BE’s profitability, $20B backlog, and asset-light shift support significant growth potential, with regulatory and execution risks to monitor. Sundry Photography/iStock Editorial via Getty Images

Investment Thesis Since my last coverage, Bloom Energy (BE) is up almost 100%, driven by its tech moat in developing solid oxide fuel cells (SOFCs), which can use various fuels as inputs in order

1.61K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2026-07-24 06:04 8d ago
2026-07-22 19:09 9d ago
Union Pacific and CN Reach Agreement to Expand Customer Opportunities in Connection with Merger
NSC Norfolk Southern Corporation
FMP Stock News
Original source text
OMAHA, Neb. & MONTREAL--(BUSINESS WIRE)--Union Pacific Railroad (NYSE: UNP) and CN (NYSE: CNI) announced today that they have signed a binding Memorandum of Understanding establishing a framework for CN to secure competitive access in connection with the proposed transaction between Union Pacific and Norfolk Southern (NYSE: NSC). The settlement agreement preserves customer options and resolves terminal railroad ownership issues, while expanding CN's presence in the Midwest and reaffirming gatew.
2026-07-24 06:04 8d ago
2026-07-23 09:00 9d ago
CELSIUS® Launches Limited-Edition SPRITZ VIBE® Summer Edition, a Sparkling Limoncello Twist Flavor Inspired by the Italian Amalfi Coast
CELH Celsius Holdings
FMP Stock News
Original source text
BOCA RATON, Fla.--(BUSINESS WIRE)--CELSIUS has launched SPRITZ VIBE Summer Edition, a limited-time only Sparkling Limoncello Twist flavor arriving just in time for the season.
2026-07-24 06:03 8d ago
2026-07-24 00:16 8d ago
Fortive: A Simplified And Accelerated Special Situation
FTV Fortive
FMP Stock News
Original source text
Fortive: A Simplified And Accelerated Special Situation
2026-07-24 06:01 8d ago
2026-07-23 16:05 8d ago
Virtu Completes Incremental First Lien Term Loan
VIRT Virtu Financial
FMP Stock News
Original source text
July 23, 2026 16:05 ET  | Source: Virtu Financial, LLC

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE: VIRT) (the “Company”), a global market maker, broker and leading provider of global financial services technology, today announced that its subsidiaries successfully priced and closed incremental term loans in the amount of $500 million (the “Incremental Term Loans”), increasing the total term loan balance under its senior secured credit facility to $2,030 million (the “Term Loans”).

The Incremental Term Loan, along with the existing Term Loans, will bear interest at Term SOFR + 250 basis points, and will be issued at par.

The proceeds of the Incremental Term Loan may be used for general corporate purposes. The Term Loans are guaranteed by Virtu Financial LLC, a subsidiary of the Company, and certain of its subsidiaries.

About Virtu Financial, Inc.

Virtu is a leading provider of financial services and products that leverages cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to its clients. Leveraging its global market making expertise and infrastructure, Virtu provides a robust product suite including offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. Virtu’s product offerings allow clients to trade on hundreds of venues across 50+ countries and in multiple asset classes, including global equities, ETFs, foreign exchange, futures, fixed income, cryptocurrency and myriad other commodities. In addition, Virtu’s integrated, multi-asset analytics platform provides a range of pre-, intra-, and post-trade services, data products and compliance tools that clients rely upon to invest, trade and manage risk across global markets.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are subject to numerous uncertainties and factors relating to the Company’s operations and business environment, as well as uncertainties relating to the Term Loans. Any forward-looking statements in this release are based upon information available to the Company on the date of this release. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any statements expressed or implied therein will not be realized.

CONTACT         

Investor Relations
Matthew Sandberg
[email protected]
2026-07-24 05:58 8d ago
2026-07-23 16:02 8d ago
AppFolio, Inc. Announces Second Quarter 2026 Financial Results
APPF Appfolio
FMP Stock News
Original source text
SANTA BARBARA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) ("AppFolio" or the "Company"), a technology leader powering the future of the real estate industry, today announced its financial results for the second quarter ended June 30, 2026.

"Our Q2 results continue to reflect our momentum with new and existing customers," said Shane Trigg, Chairman and CEO. "For the first time, we've crossed $1 billion in revenue on a trailing twelve-month basis, a milestone we believe reflects the success customers are having by adopting our products and services. The operators on our platform are embracing AI that works because it knows their business and drives real performance outcomes. That is what Real Estate Performance Management delivers."

Financial Highlights for Second Quarter of 2026

Revenue grew 19% year-over-year to $281 million.Total units under management grew 8% year-over-year to 9.6 million.GAAP operating income grew 31% to $53 million, or 18.8% of revenue, compared to $41 million, or 17.2% of revenue in Q2 2025.Non-GAAP operating income grew 24% to $76 million, or 27.1% of revenue, compared to $62 million, or 26.2% of revenue in Q2 2025.Net cash provided by operating activities was $88 million, or 31.2% of revenue, compared to $53 million, or 22.3% of revenue in Q2 2025. Financial Outlook
Based on information available as of July 23, 2026, AppFolio's outlook for fiscal year 2026 follows:

Full year revenue range is increasing to $1.117 - $1.127 billion.Full year non-GAAP operating margin range as a percentage of revenue is increasing to 26.5% - 28.0%.Diluted weighted average shares outstanding are expected to be approximately 36 million for the full year. Conference Call Information
As previously announced, the Company will host a conference call today, July 23, 2026, at 2:00 p.m. Pacific Time (PT), 5:00 p.m. Eastern Time (ET), to discuss the Company’s second quarter financial results. A live webcast of the call will be available at: https://edge.media-server.com/mmc/p/iuf6q6wf/. To access the call by phone, please go to the following link: https://register-conf.media-server.com/register/BIf2eada34bb9140a98f952424c8f0d5f1, and you will be provided with dial-in details. A replay of the webcast will also be available for a limited time on AppFolio’s Investor Relations website at https://ir.appfolioinc.com/news-events/events.

The Company also provides announcements regarding its financial results and other matters, including SEC filings, investor events, and press releases, on its Investor Relations website at https://ir.appfolioinc.com/, as a means of disclosing material nonpublic information and for complying with AppFolio's disclosure obligations under Regulation FD.

About AppFolio
AppFolio is a technology leader powering the future of the real estate industry. Our innovative platform and trusted partnership enable our customers to connect communities, increase operational efficiency, and grow their business. For more information about AppFolio, visit ir.appfolioinc.com.

Investor Relations Contact:
Lori Barker
[email protected]

Use of Non-GAAP Financial Measures
Reconciliations of current and historical non-GAAP financial measures to AppFolio’s financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. For a description of these non-GAAP financial measures, including the reasons management uses each measure, please see the section of the tables entitled “Statement Regarding the Use of Non-GAAP Financial Measures.”

AppFolio is unable, at this time, to provide GAAP equivalent guidance measures on a forward-looking basis for non-GAAP operating margin because certain items that impact this measure are uncertain, out of our control, or cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements that are not statements of historical fact contained in this press release, and can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “future’” “predicts, “projects,” “target,” “seeks,” “contemplates,” “should,” “will,” “would” or similar expressions and the negatives of those expressions. In particular, forward-looking statements contained in this press release relate to future operating results and financial position, including the Company's fiscal year 2026 financial outlook, anticipated future expenses and investments, the Company's business opportunities, the impact of the Company's strategic actions and initiatives, the potential benefits and effect of AI and its impact on the Company’s plans, objectives, expectations and capabilities.

Forward-looking statements represent AppFolio's current beliefs and expectations based on information currently available and speak only as of the date the statement is made. Forward-looking statements are subject to numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to materially differ from those expressed or implied by these forward-looking statements include those risks, uncertainties and other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 5, 2026, as such risk factors may be updated from time to time in our subsequent filings with the SEC, and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recently filed Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as well as in the Company's other filings with the SEC. You should read this press release with the understanding that the Company's actual future results may be materially different from the results expressed or implied by these forward-looking statements.

The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(in thousands)
  June 30,
2026 December 31,
2025Assets    Current assets    Cash and cash equivalents $217,401 $106,967Investment securities—current  4,284  144,256Accounts receivable, net  50,442  36,873Prepaid expenses and other current assets  53,058  65,218Total current assets  325,185  353,314Property and equipment, net  21,464  23,228Operating lease right-of-use assets  14,798  15,924Capitalized software development costs, net  11,444  11,324Goodwill  96,410  96,410Intangible assets, net  33,711  38,826Deferred income taxes  42,819  58,823Long-term investments  87,668  77,033Other long-term assets  14,872  14,085Total assets $648,371 $688,967Liabilities and Stockholders’ Equity    Current liabilities    Accounts payable $4,776 $4,123Accrued employee expenses  30,010  59,774Accrued expenses  26,990  20,829Other current liabilities  23,106  22,121Total current liabilities  84,882  106,847Operating lease liabilities  30,660  33,287Other liabilities  6,687  6,254Total liabilities  122,229  146,388Stockholders’ equity  526,142  542,579Total liabilities and stockholders’ equity $648,371 $688,967 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share amounts)

 Three Months Ended
June 30, Six Months Ended
June 30,  2026   2025   2026  2025Revenue(1)$281,124  $235,575  $543,338 $453,277Costs and operating expenses:       Cost of revenue (exclusive of depreciation and amortization)(2) 102,595   83,827   197,570  163,325Sales and marketing(2) 43,944   36,776   81,445  67,833Research and product development(2) 50,997   46,674   100,626  90,432General and administrative(2) 25,626   21,936   49,967  45,287Depreciation and amortization 4,985   5,850   10,005  12,105Total costs and operating expenses 228,147   195,063   439,613  378,982Income from operations 52,977   40,512   103,725  74,295Other (loss) income, net (1)  (11)  568  45Interest income, net 1,435   1,466   3,219  4,419Income before provision for income taxes 54,411   41,967   107,512  78,759Provision for income taxes 12,867   5,987   23,544  11,396Net income$41,544  $35,980  $83,968 $67,363Net income per common share:       Basic$1.17  $1.00  $2.36 $1.87Diluted$1.17  $0.99  $2.36 $1.85Weighted average common shares outstanding       Basic 35,391   35,922   35,544  36,111Diluted 35,461   36,204   35,635  36,425
(1) The following table presents our revenue categories:

 Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Subscription Services$59,800 $52,473 $118,022 $101,986Value Added Services 219,467  180,145  420,830  344,851Other 1,857  2,957  4,486  6,440Total revenue$281,124 $235,575 $543,338 $453,277
(2) Includes stock-based compensation expense as follows:

 Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Costs and operating expenses:       Cost of revenue (exclusive of depreciation and amortization)$1,246 $1,419 $2,334 $2,706Sales and marketing 3,633  3,045  6,973  5,893Research and product development 8,918  8,176  16,800  15,107General and administrative 6,674  5,659  12,353  10,964Total stock-based compensation expense$20,471 $18,299 $38,460 $34,670 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands) Three Months Ended
June 30, Six Months Ended
June 30,  2026   2025   2026   2025 Cash from operating activities       Net income$41,544  $35,980  $83,968  $67,363 Adjustments to reconcile net income to net cash provided by operating activities:       Depreciation and amortization 4,985   5,850   10,005   12,105 Amortization of operating lease right-of-use assets 566   507   1,126   1,008 Amortization of costs capitalized to obtain revenue contracts, net 3,300   2,699   6,468   5,419 Deferred income taxes 7,976   (7,644)  16,004   (13,185)Stock-based compensation, including as amortized 20,471   18,299   38,460   34,670 Other —   (131)  (523)  (1,048)Changes in operating assets and liabilities:       Accounts receivable (6,475)  (5,081)  (13,918)  (8,197)Prepaid expenses and other assets (1,887)  (5,966)  (10,093)  (11,426)Accounts payable 1,035   (1,694)  653   852 Operating lease liabilities (1,204)  (1,051)  (2,384)  (2,102)Accrued expenses and other liabilities 17,293   10,875   (7,864)  5,649 Net cash provided by operating activities 87,604   52,643   121,902   91,108 Cash from investing activities       Purchases of available-for-sale investments (3,277)  (1,732)  (45,940)  (64,034)Proceeds from sales of available-for-sale investments —   99,944   140,154   202,662 Proceeds from maturities of available-for-sale investments 3,230   1,670   45,590   43,820 Purchases of property and equipment 3   (275)  (228)  (505)Capitalization of software development costs (1,250)  (842)  (2,554)  (1,478)Purchases of long-term investments (10,000)  (75,000)  (10,000)  (75,000)Cash paid in business acquisition, net of cash acquired —   —   —   (906)Net cash (used in) provided by investing activities (11,294)  23,765   127,022   104,559 Cash from financing activities       Proceeds from stock option exercises and the issuance of common stock under the Employee Stock Purchase Plan —   117   998   128 Tax withholding for net share settlement (6,321)  (10,020)  (14,478)  (19,098)Purchase of common stock —   (49,960)  (125,010)  (145,723)Net cash used in financing activities (6,321)  (59,863)  (138,490)  (164,693)Net increase in cash, cash equivalents and restricted cash 69,989   16,545   110,434   30,974 Cash, cash equivalents and restricted cash       Beginning of period 147,662   57,183   107,217   42,754 End of period$217,651  $73,728  $217,651  $73,728    RECONCILIATION FROM GAAP TO NON-GAAP RESULTS
(UNAUDITED)
(in thousands, except per share data)

   Three Months Ended
June 30, Six Months Ended
June 30,    2026   2025   2026   2025 Costs and operating expenses:      GAAP cost of revenue (exclusive of depreciation and amortization)$102,595  $83,827  $197,570  $163,325   Stock-based compensation expense (1,246)  (1,419)  (2,334)  (2,706) Non-GAAP cost of revenue (exclusive of depreciation and amortization)$101,349  $82,408  $195,236  $160,619  GAAP cost of revenue (exclusive of depreciation and amortization) as a percentage of revenue 36%  36%  36%  36% Non-GAAP cost of revenue (exclusive of depreciation and amortization) as a percentage of revenue 36%  35%  36%  35%           GAAP sales and marketing$43,944  $36,776  $81,445  $67,833   Stock-based compensation expense (3,633)  (3,045)  (6,973)  (5,893) Non-GAAP sales and marketing$40,311  $33,731  $74,472  $61,940  GAAP sales and marketing as a percentage of revenue 16%  16%  15%  15% Non-GAAP sales and marketing as a percentage of revenue 14%  14%  14%  14%           GAAP research and product development$50,997  $46,674  $100,626  $90,432   Stock-based compensation expense (8,918)  (8,176)  (16,800)  (15,107) Non-GAAP research and product development$42,079  $38,498  $83,826  $75,325  GAAP research and product development as a percentage of revenue 18%  20%  19%  20% Non-GAAP research and product development as a percentage of revenue 15%  16%  15%  17%           GAAP general and administrative$25,626  $21,936  $49,967  $45,287   Stock-based compensation expense (6,674)  (5,659)  (12,353)  (10,964) Non-GAAP general and administrative$18,952  $16,277  $37,614  $34,323  GAAP general and administrative as a percentage of revenue 9%  9%  9%  10% Non-GAAP general and administrative as a percentage of revenue 7%  7%  7%  8%           GAAP depreciation and amortization$4,985  $5,850  $10,005  $12,105   Amortization of stock-based compensation capitalized in software development costs (241)  (241)  (482)  (482)  Amortization of purchased intangibles (2,558)  (2,558)  (5,115)  (5,115) Non-GAAP depreciation and amortization$2,186  $3,051  $4,408  $6,508  GAAP depreciation and amortization as a percentage of revenue 2%  2%  2%  3% Non-GAAP depreciation and amortization as a percentage of revenue 1%  1%  1%  1%    Three Months Ended
June 30, Six Months Ended
June 30,    2026   2025   2026   2025 Income from operations:        GAAP income from operations$52,977  $40,512  $103,725  $74,295   Stock-based compensation expense 20,471   18,299   38,460   34,670   Amortization of stock-based compensation capitalized in software development costs 241   241   482   482   Amortization of purchased intangibles 2,558   2,558   5,115   5,115  Non-GAAP income from operations$76,247  $61,610  $147,782  $114,562           Operating margin:        GAAP operating margin 18.8%  17.2%  19.1%  16.4%  Stock-based compensation expense as a percentage of revenue 7.3   7.8   7.1   7.7   Amortization of stock-based compensation capitalized in software development costs as a percentage of revenue 0.1   0.1   0.1   0.1   Amortization of purchased intangibles as a percentage of revenue 0.9   1.1   0.9   1.1  Non-GAAP operating margin 27.1%  26.2%  27.2%  25.3%          Net income (loss):        GAAP net income$41,544  $35,980  $83,968  $67,363   Stock-based compensation expense 20,471   18,299   38,460   34,670   Amortization of stock-based compensation capitalized in software development costs 241   241   482   482   Amortization of purchased intangibles 2,558   2,558   5,115   5,115   Income tax effect of adjustments (4,223)  (7,257)  (9,801)  (13,599) Non-GAAP net income$60,591  $49,821  $118,224  $94,031           Net income per share, basic:        GAAP net income per share, basic$1.17  $1.00  $2.36  $1.87   Non-GAAP adjustments to net income 0.54   0.39   0.97   0.73  Non-GAAP net income per share, basic$1.71  $1.39  $3.33  $2.60           Net income per share, diluted:        GAAP net income per share, diluted$1.17  $0.99  $2.36  $1.85   Non-GAAP adjustments to net income 0.54   0.39   0.96   0.73  Non-GAAP net income per share, diluted$1.71  $1.38  $3.32  $2.58            Weighted-average shares used in GAAP and non-GAAP per share calculation         Basic 35,391   35,922   35,544   36,111   Diluted 35,461   36,204   35,635   36,425 
Statement Regarding the Use of Non-GAAP Financial Measures

We use the following non-GAAP financial measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Non-GAAP presentation of income from operations, costs and operating expenses, operating margin, net income, and net income per share. These measures exclude certain non-cash or non-recurring items, including stock-based compensation expense, amortization of stock-based compensation capitalized in software development costs, amortization of purchased intangibles, and the related income tax effect of these adjustments, as applicable and described below. Non-GAAP operating margin is calculated as non-GAAP operating income from operations as a percentage of revenue. We use each of these non-GAAP financial measures internally to assess and compare operating results across reporting periods, for internal budgeting and forecasting purposes, and to evaluate our financial performance. We believe these non-GAAP financial measures also provide useful supplemental information to investors and facilitate the analysis of our operating results and comparison of operating results across reporting periods.

In particular, we believe these non-GAAP financial measures are useful to investors and others in assessing our operating performance due to the following factors:

Stock-based compensation expense and amortization of stock-based compensation capitalized in software development costs. We utilize stock-based compensation to attract and retain employees. It is principally aimed at aligning their interests with those of our stockholders while ensuring long-term retention, rather than to address operational performance for any particular period. As a result, stock-based compensation expenses vary for reasons that are generally unrelated to financial and operational performance in any particular period. Amortization of purchased intangibles. We view amortization of purchased intangible assets as items arising from pre-acquisition activities determined at the time of an acquisition. While these intangible assets are evaluated for impairment regularly, amortization of the cost of purchased intangibles is an expense that is not typically affected by operations during any particular period. Income tax effects of adjustments. We utilize a fixed long-term projected tax rate in our computation of non-GAAP income tax effects to provide better consistency across interim reporting periods. In projecting this long-term non-GAAP tax rate, we utilize a financial projection that excludes the direct impact of other non-GAAP adjustments. The projected rate, which we have determined to be 22% and 21% for 2026 and 2025, respectively, considers other factors such as our current operating structure, existing tax positions in various jurisdictions, and key legislation in major jurisdictions where we operate. We periodically re-evaluate this tax rate, as necessary, for significant events, based on relevant tax law changes, and material changes in the forecasted geographic earnings mix. Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies may calculate non-GAAP financial results differently. In addition, there are limitations in using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and can exclude expenses that may have a material impact on our reported financial results. As such, non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. A reconciliation of the historical non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the tables above. We encourage investors to review the reconciliation of these historical non-GAAP financial measures to their most directly comparable GAAP financial measures.
2026-07-24 05:58 8d ago
2026-07-23 14:00 8d ago
L3Harris Announces Quarterly Dividend
LHX L3Harris Technologies
FMP Stock News
Original source text
MELBOURNE, Fla.--(BUSINESS WIRE)--The Board of Directors of L3Harris Technologies (NYSE: LHX) has declared a quarterly cash dividend of $1.25 per common share, payable Sept. 18, 2026, to shareholders of record as of the close of business on Sept. 4, 2026. About L3Harris Technologies L3Harris is the Trusted Disruptor in defense tech. With customers' mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains.
2026-07-24 05:53 8d ago
2026-07-23 16:15 8d ago
GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
GEHC GE HealthCare Technologies
FMP Stock News
Original source text
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Jay Saccaro will step down as Vice President and Chief Financial Officer for an expanded role outside of the medical technology industry. The Company has appointed George Newcomb, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer. Mr. Saccaro will remain with the Company through August 14, 2026, and work together with Mr. Newcomb to ensure a smooth transition. GE HealthCare has commen.
2026-07-24 05:52 8d ago
2026-07-23 10:00 9d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ON Semiconductor Corporation - ON
ON ON Semiconductor
FMP Stock News
Original source text
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ON Semiconductor Corporation ("Onsemi" or the "Company") (NASDAQ: ON). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Onsemi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 25, 2026, Onsemi announced an agreement to buy the internet-of-things company Synaptics Incorporated ("Synaptics") in an all-stock transaction.  Pursuant to the terms of the agreement, Synaptics shareholders will receive 1.35 shares of Onsemi stock for each Synaptics share, representing an enterprise value of around $7 billion. 

Following announcement of the agreement, Onsemi's stock price fell $28.09 per share, or 23.66%, to close at $90.65 per share on June 26, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP
2026-07-24 05:51 8d ago
2026-07-23 03:00 9d ago
Teledyne Announces Strategic Five-Year Partnership with Royal National Lifeboat Institution, the UK's Largest Lifeboat Service
TDY Teledyne Technologies
FMP Stock News
Original source text
FAREHAM, England--(BUSINESS WIRE)--Teledyne Raymarine and Teledyne FLIR Marine today announced a strategic five-year partnership with the Royal National Lifeboat Institution (RNLI), the largest lifeboat service operating around the coast of the United Kingdom, Ireland and the Channel Islands, to deliver advanced navigation and thermal imaging technologies to its fleet of vessels, enhancing the charity's ability to respond swiftly and effectively in lifesaving operations at sea.The integration of.
2026-07-24 05:51 8d ago
2026-07-23 16:05 8d ago
Huntington Bancshares Incorporated Declares Quarterly Cash Dividends On Its Common and Preferred Stocks
HBAN Huntington
FMP Stock News
Original source text
, /PRNewswire/ -- Huntington Bancshares Incorporated announced that the Board of Directors ("Board") declared a quarterly cash dividend on the company's common stock (Nasdaq: HBAN) of $0.155 per common share, unchanged from the prior quarter. The common stock cash dividend is payable October 1, 2026, to shareholders of record on September 17, 2026.

The Board also declared quarterly cash dividends on the following six series of its preferred stock payable October 15, 2026, to their respective shareholders of record on October 1, 2026:

A quarterly cash dividend on its Floating Rate Series B Non-Cumulative Perpetual Preferred Stock (CUSIP#: 446150500) of $16.78632394 per share (equivalent to $0.4196581 per depositary receipt share). A quarterly cash dividend on its 5.625% Series F Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (CUSIP#: 446150AT1) of $1,406.25 per share (equivalent to $14.0625 per depositary share). A quarterly cash dividend on its 4.450% Series G Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (CUSIP#: 446150AV6) of $1,112.50 per share (equivalent to $11.1250 per depositary share). A quarterly cash dividend on its 4.5% Series H Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANP) of $11.25 per share (equivalent to $0.28125 per depositary share). A quarterly cash dividend on its 6.875% Series J Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANL) of $17.19 per share (equivalent to $0.42975 per depositary share). A quarterly cash dividend on its 6.25% Series K Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (CUSIP#: 446150BG8) of $1,562.50 per share (equivalent to $15.625 per depositary share). Lastly, the Board declared a quarterly cash dividend on the company's 5.50% Series L Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANZ) of $343.75 per share (equivalent to $0.34375 per depositary share) payable November 20, 2026, to shareholders of record on November 5, 2026.

About Huntington

Huntington Bancshares Incorporated is a $284 billion asset regional bank holding company headquartered in Columbus, Ohio. A top 10 U.S. commercial bank, the Huntington National Bank and its affiliates provide consumers, small and middle-market businesses, corporations, municipalities, and other organizations with a comprehensive suite of banking, payments, wealth management, and risk management products and services. Founded in 1866, Huntington operates over 1,400 branches in 21 states, with certain businesses operating nationally. Visit Huntington.com for more information.

SOURCE Huntington Bancshares Incorporated
2026-07-24 05:50 8d ago
2026-07-23 16:05 8d ago
Wintrust Financial Corporation Announces Cash Dividends
WTFC Wintrust Financial Corporation
FMP Stock News
Original source text
July 23, 2026 16:05 ET  | Source: Wintrust Financial Corporation

ROSEMONT, Ill., July 23, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Wintrust Financial Corporation (“Wintrust” or the “Company”) (Nasdaq: WTFC) has approved a quarterly cash dividend of $0.55 per share of outstanding common stock. The dividend is payable on August 20, 2026, to shareholders of record as of August 6, 2026.

Additionally, the Company’s Board of Directors approved a cash dividend on outstanding shares of the Company’s 7.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series F. The dividend is payable on October 15, 2026, to shareholders of record as of October 1, 2026.

About Wintrust

Wintrust is a financial holding company with $74.7 billion in assets whose common stock is traded on the Nasdaq Global Select Market. Guided by its “Different Approach, Better Results®” philosophy, Wintrust offers the sophisticated resources of a large bank while providing a community banking experience to each customer. Wintrust operates more than 200 retail banking locations through 16 community bank subsidiaries in the greater Chicago, southern Wisconsin, west Michigan, northwest Indiana, and southwest Florida market areas. In addition, Wintrust operates various non-bank business units, providing residential mortgage origination, wealth management, commercial and life insurance premium financing, short-term accounts receivable financing/outsourced administrative services to the temporary staffing services industry, and qualified intermediary services for tax-deferred exchanges. For more information, please visit wintrust.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that such statements are predictions and that actual events or results may differ materially. Wintrust's expected financial results or other plans are subject to a number of risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" and the forward-looking statement disclosure contained in Wintrust's Annual Report on Form 10-K for the most recently ended fiscal year and in Wintrust’s subsequent Quarterly Report on Form 10-Q. Forward-looking statements speak only as of the date made and Wintrust undertakes no duty to update the information.

FOR MORE INFORMATION CONTACT:
David A. Dykstra, Vice Chairman & Chief Operating Officer
(847) 939-9000
Amy Yuhn, Executive Vice President, Communications
(847) 939-9591
Website address: www.wintrust.com
2026-07-24 05:48 8d ago
2026-07-23 23:40 8d ago
Time To Shine For CMT Preferreds
VLY Valley National Bancorp
FMP Stock News
Original source text
HomeDividends AnalysisDividend Quick Picks

SummaryThe Fed's recent hawkish pivot sharply increased interest rates, negatively impacting most income sectors.CMT preferreds emerge as a compelling sub-sector, offering potential protection against rising long-term rates.Screening CMT preferreds by reset yield and yield-to-call can help identify attractive opportunities.Looking for a portfolio of ideas like this one? Members of Systematic Income get exclusive access to our subscriber-only portfolios. Learn More » Getty Images

In Kevin Warsh's first press conference in June, the Fed shocked markets and made a hawkish pivot, pushing up interest rates across the yield curve. This development was received badly by most income sectors. This is what the daily move looked

13.67K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AGNCL,EFC.PR.B,KEY.PR.L,VLYPN,RITM.PR.D either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2026-07-24 05:47 8d ago
2026-07-23 09:22 9d ago
DEADLINE NEXT WEEK: Berger Montague Advises AeroVironment, Inc. (NASDAQ: AVAV) Investors to Contact the Firm Before July 27, 2026
AVAV AeroVironment
FMP Stock News
Original source text
, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against AeroVironment, Inc. (NASDAQ: AVAV) ("AeroVironment" or the "Company") on behalf of investors who purchased or acquired AeroVironment common stock during the period from June 25, 2025 through March 10, 2026 (the "Class Period").

Investor Deadline: Investors who purchased or acquired AeroVironment common stock during the Class Period may, no later than July 27, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Based in Arlington, Va., AeroVironment is a leading American defense technology company specializing in autonomous systems and unmanned aircraft systems (UAS) and space and directed-energy technologies serving the U.S. Department of Defense, allied governments, and commercial customers globally.

On January 20, 2026, AeroVironment disclosed that the U.S. government had issued a stop work order on the Company's agreement to deliver BADGER systems to the Satellite Communication Augmentation Resource ("SCAR") program. While AeroVironment stated that it expected to continue delivering capabilities under the program, its stock price fell 15.77% on January 20, 2026, closing at $330.89 per share — a decline of $61.97.

On March 2, 2026, Space News reported that the U.S. Space Force was reopening the SCAR program and "reassessing how to move forward," with Colonel Owen Stevens of the Space Rapid Capabilities Office confirming that the Space Force would "move into a new acquisition strategy for SCAR." Following this report, AeroVironment's stock price fell 17.42% on March 2, 2026, closing at $208.32 per share — a drop of $43.93.

On March 10, 2026, AeroVironment reported a third quarter 2026 operating loss of $179.0 million for fiscal year 2026, inclusive of a $151.3 million goodwill impairment in its space division. The Company also disclosed that the Space Force had formally terminated its SCAR contract and that AeroVironment would be required to "recompete" for the program. On this news, AeroVironment's stock fell 6.24% on March 11, 2026, closing at $207.73 per share.

If you are an AeroVironment investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Berger Montague
(215) 875-3015
[email protected] 

Caitlin Adorni
Berger Montague
(267)764-4865
[email protected]

SOURCE Berger Montague
2026-07-24 05:46 8d ago
2026-07-23 01:30 9d ago
Freedom Holding Corp. Works With Ant International's Antom to Simplify Online Shopping From China for Kazakhstan Consumers
FRHC Freedom Holding
FMP Stock News
Original source text
ALMATY, Kazakhstan & SHANGHAI--(BUSINESS WIRE)--On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. Antom will promote Freedom Bank Sup.
2026-07-24 05:44 8d ago
2026-07-24 05:39 8d ago
Moneta zvýšila čistý zisk o 8,1 procenta a navýšila celoroční výhled
MONET Moneta
Patria Stock News
Original source text
Moneta Money Bank vykázala za první letošní pololetí čistý zisk 3,3 miliardy korun, což je meziročně o 8,1 procenta více. Výsledky podpořily především vyšší provozní výnosy, zatímco provozní náklady zůstaly prakticky beze změny. Banka zároveň potvrdila celoroční výhled a nově očekává, že původně stanovený cíl překoná.

Provozní výnosy skupiny vzrostly meziročně o 6,5 procenta na 7,2 miliardy korun. Čistý úrokový výnos se zvýšil o 8,5 procenta na 5,2 miliardy korun díky růstu objemu nově poskytnutých úvěrů a úpravě sazeb v hypotečním portfoliu. Čistá úroková marže za první pololetí dosáhla dvou procent.

Pozitivní vývoj zaznamenaly také poplatky a provize z investičních produktů, kde čistý výnos stoupl o 6,2 procenta na 1,8 miliardy korun. Výnosy z jejich distribuce vzrostly o třetinu na 544 milionů korun. Výnosy z distribuce pojištění dosáhly 598 milionů korun.
Celkové provozní náklady zůstaly na úrovni 2,9 miliardy korun. Vyšší personální náklady, které vzrostly o 8,8 procenta na 1,3 miliardy korun, kompenzovaly nižší odpisy a pokles správních nákladů. Regulované poplatky meziročně vzrostly o 8,7 procenta na 212 milionů korun.

Náklady na riziko dosáhly 414 milionů korun, což odpovídá 28 bazickým bodům průměrného čistého úvěrového portfolia. Banka uvedla, že meziroční růst ovlivnilo především selhání jednoho komerčního klienta. Podíl úvěrů v selhání se však dále snížil na 0,9 procenta. Prodeje problémových pohledávek v nominální hodnotě 716 milionů korun zároveň přinesly mimořádný výnos 58,5 milionu korun.

Výrazně rostla úvěrová aktivita. Moneta poskytla nové úvěry v celkovém objemu 51,7 miliardy korun, což je o 43,9 procenta více než před rokem. Nově poskytnuté hypotéky zaznamenaly růst o 61,8 procenta na 14,6 miliardy korun, zatímco objem spotřebitelských a ostatních retailových úvěrů se zvýšil o 23,3 procenta na 15,3 miliardy korun. V případě malých a středních podniků se objem nových úvěrů zvýšil o 58,2 procenta na 16,6 miliardy korun.

Celkové úvěrové portfolio banky meziročně vzrostlo o 9,1 procenta na 310 miliard korun. Rychleji rostl komerční segment, jehož objem se zvýšil o 18,5 procenta na 116 miliard korun. Retailové úvěry vzrostly o 4,2 procenta na 193 miliard korun.

Silnou dynamiku si nadále udržuje oblast investic. Klienti banky investovali během prvního pololetí do podílových fondů 10,9 miliardy korun a celkový objem prostředků ve fondech ke konci června dosáhl 88,7 miliardy korun, meziročně o 31,5 procenta více.

Banka současně v červnu vydala nástroj dodatečného kapitálu Tier 1 (AT1) v objemu 150 milionů eur. Emise byla podle banky trojnásobně přeupsána a agentura Moody's jí přidělila rating Ba1. Získané prostředky mají podpořit další růst úvěrového portfolia.

Představenstvo zároveň potvrdilo střednědobý výhled pro období 2026 až 2030. Pro letošek Moneta nadále míří k čistému zisku 6,6 miliardy korun, nově ale očekává, že tento cíl překoná přibližně o 200 milionů korun. K lepšímu výsledku mají přispět především vyšší úrokové výnosy z rychlejšího růstu úvěrového portfolia a nižší než plánované provozní náklady.
2026-07-24 05:37 8d ago
2026-07-23 10:00 9d ago
Pinnacle Financial Partners adds experienced revenue producers in second quarter as growth model continues to accelerate
PNFP Pinnacle Financial Partners
FMP Stock News
Original source text
ATLANTA--(BUSINESS WIRE)---- $PNFP--Pinnacle Financial Partners (NYSE: PNFP) added 74 experienced revenue-producing team members during the second quarter of 2026, bringing its year-to-date total to 124 against a goal of 225-250 for the year. This success is another milestone as the firm continues to execute its long-standing growth strategy following its merger with Synovus Financial Corp. in January. These new team members average approximately 20 years of financial services experience and are nearly e.
2026-07-24 05:35 8d ago
2026-07-23 16:00 8d ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in Badger Meter, Inc. Lawsuit - BMI
BMI Badger Meter
FMP Stock News
Original source text
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP highlights the contrast between Badger Meter, Inc.'s (NYSE: BMI) promises to shareholders and the results that ultimately materialized. Find out if you can recover your Badger Meter investment losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

BMI shares collapsed more than 24%, losing $36.75 per share on April 17, 2026, after the company disclosed total sales fell 9% year-over-year and utility water revenue dropped 10%. The lead plaintiff deadline is August 3, 2026.

The Promise

Throughout 2024 and into early 2025, Badger Meter's leadership painted a picture of durable, accelerating growth for investors. The company projected "high single-digit average top line growth" supported by what it described as "ongoing favorable industry fundamentals" and "secular growth drivers." Management characterized demand as "robust" and told the market its order book and opportunity pipeline "continue to support" the growth outlook. On the 1Q 2025 earnings call, the company went further, directly rejecting the possibility that customers were pulling orders forward, asserting that 75% of revenue went to end users who "really, in many ways, cannot pull forward."

The Reality

The company's actual trajectory told a different story:

Promised: "High single-digit average top line growth" sustained by secular demandDelivered: Total sales declined 9% year-over-year in 1Q 2026Promised: Utility water revenue driven by "robust adoption rates" and "solid demand"Delivered: Utility water sales fell 10% year-over-year in 1Q 2026Promised: Operating margins expanding on "strong operating execution"Delivered: Operating margin contracted from 22.2% to 17.4% in one yearPromised: EPS growth trajectory; 1Q 2025 delivered $1.30 diluted EPSDelivered: Diluted EPS fell to $0.93 in 1Q 2026, a 28% declinePromised: No evidence of customer order pull-forward; "pretty normal order environment"Delivered: Management acknowledged $15 million to $20 million of revenue shortfall from "softer short-cycle municipal customer ordering" What the Lawsuit Contends About the Gap

The securities action alleges that Badger Meter's "record" results during the Class Period were not the product of genuine demand growth but were instead inflated by pulling forward customer orders, which depleted revenue from future periods. When backlog cushions thinned and short-cycle ordering weakened, the complaint asserts, the company could no longer mask the underlying deterioration. Management itself eventually conceded that the demand "variability" seen in 1Q 2026 "has always existed" during 2023-2025 but was "less visible" due to backlog levels and projects in flight.

"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The contrast between what Badger Meter communicated about its growth trajectory and what ultimately occurred raises serious questions for shareholders." — Joseph E. Levi, Esq.

Speak with an attorney about recovering your BMI losses or call (212) 363-7500.

LEAD PLAINTIFF DEADLINE: August 3, 2026

About Levi & Korsinsky, LLP

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the BMI Lawsuit

Q: What specific misstatements does the BMI lawsuit allege? A: The complaint alleges Badger Meter made materially false or misleading statements regarding the sustainability of its revenue growth, the strength of customer demand, and the absence of order pull-forward practices during the class period from April 18, 2024 through April 16, 2026. When the true state of demand was revealed, the stock price declined sharply.

Q: How much did BMI stock drop? A: Shares fell more than 24%, a decline of $36.75 per share, on April 17, 2026, after the company disclosed that total sales were 9% lower year-over-year and that short-cycle order rates were "weaker than anticipated." Across three corrective disclosures, BMI lost over $95 per share.

Q: What do BMI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my BMI shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting Levi & Korsinsky before August 3, 2026 ensures your losses are considered.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-717
2026-07-24 05:32 8d ago
2026-07-23 16:33 8d ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Planet Fitness, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PLNT
PLNT Planet Fitness
FMP Stock News
Original source text
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Planet Fitness, Inc. (NYSE: PLNT) between November 6, 2025 and May 6, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 14, 2026.

SO WHAT: If you purchased Planet Fitness common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Planet Fitness class action, go to https://rosenlegal.com/cases/planet-fitness-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Planet Fitness’ customer acquisition and marketing metrics. Notably, Planet Fitness’ updated marketing messaging was failing to resonate with, and was actively intimidating, its core target demographic of fitness beginners and casual gym-goers. As a result, Planet Fitness was experiencing a significant headwind in net member joins during its peak first-quarter sign-up period that rendered its previously issued fiscal 2026 guidance and long term financial targets unachievable. Instead, Planet Fitness would be required to restructure its marketing strategy, losing the gains they praised from continuing the same marketing campaign, and entirely halt the planned Black Card price increase which sale projections were premised upon. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Planet Fitness class action, go to https://rosenlegal.com/cases/planet-fitness-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com
2026-07-24 05:31 8d ago
2026-07-23 09:00 9d ago
Twilio Research Finds 88% of Government Organizations Rate Their Citizen Engagement as Good or Excellent, but Only 44% of Citizens Agree
TWLO Twilio
FMP Stock News
Original source text
SAN FRANCISCO--(BUSINESS WIRE)--Research from Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, shows a stark perception gap in the public sector: while 88% of government organizations rate their citizen engagement as good or excellent, only 44% of citizens agree. The Connected Government Report (2026) shows that while public sector agencies are confident in their digital services, citizens report fewer tangible benefits from digital interactions than in previous yea.
2026-07-24 05:30 8d ago
2026-07-23 09:00 9d ago
SentinelOne Named a Leader in the IDC MarketScape for Worldwide Managed Detection and Response Service for Midmarket
S SentinelOne
FMP Stock News
Original source text
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SentinelOne® (NYSE: S), the AI Security leader, today announced it has been named a Leader in the IDC MarketScape: Worldwide Managed Detection and Response Service for Midmarket 2026 Vendor Assessment (Doc #US52992326, July 2026). The IDC MarketScape covers Wayfinder, SentinelOne's managed detection and response (MDR) offering, which uses AI to handle detection, correlation, and triage at machine speed, and SentinelOne's analysts to apply human judgment t.
2026-07-24 05:26 8d ago
2026-07-23 10:00 9d ago
Nexstar Announces Completion of ATSC 3.0 Transition in Cleveland, Marking Upgrade in Final Major U.S. Market
NXST Nexstar Broadcasting Group
FMP Stock News
Original source text
IRVING, Texas--(BUSINESS WIRE)--Nexstar Media Group, Inc. (NASDAQ: NXST), today announced the successful launch of ATSC 3.0 (NextGen TV) in the Cleveland, Ohio, television market, with the next-generation broadcast standard now deployed across all of the top 25 U.S. designated market areas (DMAs). As the largest remaining market yet to deploy ATSC 3.0, Cleveland had been unable to launch due to structural limitations in available broadcast spectrum and station participation. However, following.
2026-07-24 05:15 8d ago
2026-07-23 16:05 8d ago
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
ROIV Roivant Sciences
FMP Stock News
Original source text
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens.
2026-07-24 04:55 8d ago
2026-07-23 22:40 8d ago
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
SMMT Summit Therapeutics
FMP Stock News
Original source text
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call July 23, 2026 4:30 PM EDT

Company Participants

Dave Gancarz - Chief Business & Strategy Officer
Robert Duggan - Co-CEO & Executive Chairman
Mahkam Zanganeh - Co-CEO, President & Director
Manmeet Soni - COO, CFO & Director
Allen Yang - Chief R&D Strategy Officer

Conference Call Participants

Yigal Nochomovitz - Citigroup Inc., Research Division
Nicholas Lorusso - TD Cowen, Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Bradley Canino - Guggenheim Securities, LLC, Research Division
William Zhang - Wells Fargo Securities, LLC, Research Division
David Dai
Reni Benjamin - Citizens JMP Securities, LLC, Research Division
Eric Schmidt - Cantor Fitzgerald & Co., Research Division
Dara Azar - Stifel, Nicolaus & Company, Incorporated, Research Division
Faisal Khurshid - Jefferies LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to Summit Therapeutics Q2 2026 Earnings Call. [Operator Instructions] We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates. Please note that today's call is being recorded. [Operator Instructions]

At this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics Chief Business and Strategy Officer. You may proceed.

Dave Gancarz
Chief Business & Strategy Officer

Good afternoon, and thank you for joining us. On today's call, we will provide an update on our second quarter 2026 financial results and operational progress. This afternoon's press release is available on our website, www.smmttx.com. Our Form 10-Q was also filed today and is available on our website and via the SEC's website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website.

Joining me on the call today is Bob
2026-07-24 04:45 8d ago
2026-07-23 23:04 8d ago
Comstock Q2 Earnings Call Highlights
LODE Comstock
FMP Stock News
Original source text
3 Micro-Caps Set for Major Moves: Balancing Risk and OpportunityComstock NYSEAMERICAN: LODE executives said the company ended the second quarter of 2026 with a stronger balance sheet, completed major capital spending on its first industry-scale solar panel recycling facility and remains focused on monetizing legacy mining and real estate-related assets.

Chief Financial Officer Judd Merrill said Comstock ended the quarter with approximately $31.4 million in cash and no debt. Total working capital was $39.9 million, based on $58.1 million in current assets and $18.2 million in current liabilities.

Get Comstock alerts:

Merrill said the company expects another $20 million in cash in August upon closing a securities purchase agreement tied to the sale of 100% of its legacy mining assets to Mackay Precious Metals. He said the transaction would also remove mining reclamation liabilities, bonding requirements and related costs from Comstock’s balance sheet, while allowing the company to retain upside through net smelter return royalties across the district and equity in Mackay.

“The mining sale will also eliminate annual costs of about $1.4 million and free our capacity to focus more on the recycling business,” Merrill said.

Capital Deployment Focused on Metals and Sierra Springs Merrill said Comstock’s largest source of cash during the first half of the year was its January equity financing, which generated approximately $56 million in net proceeds. The company also generated nearly $6.5 million in additional proceeds, including more than $2 million from mining asset sales, $1.8 million from debt extinguishment-related recoveries and $2.6 million in solar panel recycling revenue, including deferred revenue from Comstock Metals.

On the spending side, Merrill said the company invested approximately $21 million into Sierra Springs, enabling the closing of more than 2,200 acres of land and nearly 2,000 acre-feet of water rights. The investment increased Comstock’s ownership in Sierra Springs to nearly 50%, according to the company.

Comstock also spent approximately $5 million completing its first industry-scale metals recycling facility, $1.3 million expanding product upgrade capabilities, approximately $1.4 million advancing new metals recovery technologies and approximately $3 million on metals operating costs as operations ramped.

Merrill said Comstock was added to the Russell 2000 and Russell 3000 indexes in late June, which the company views as a step in strengthening its institutional capital base.

Solar Panel Recycling Facility Set to Begin Continuous Operations Chief Executive Officer Corrado De Gasperis said Comstock’s first industry-scale solar panel recycling system is expected to begin ramping in August after final testing and commissioning. He said the system is designed for 100,000 tons of annual capacity and that the company expects to operate at about 25% capacity initially.

De Gasperis said the company’s process is designed to remove contaminants and produce clean, saleable materials, including glass and metals. He said Comstock’s product upgrade systems are already operating and have been stress-tested, allowing the company to produce higher-specification glass while recovering additional residual materials.

Merrill said the company’s new storage area is graded, fenced and ready to open, with total panels on the ground and ready for processing approaching 9,000 tons. De Gasperis later said panels are stored across sites including California and Ohio, but the company is not disclosing volumes by location.

In response to investor questions, Merrill said the metals operation begins generating cash from an operational standpoint when the first plant reaches a little more than 20% capacity. He said the company-wide cash flow threshold from plant one is roughly 40% to 50% of operations.

De Gasperis said Comstock is not guiding beyond 25% capacity for the year-end ramp, though he said the company has incentives to push higher. “Getting to 25% proves what most people are looking to see,” he said, citing whether the machine works reliably and profitably at the line-of-business level.

Management Discusses Customers, Competition and Future Sites De Gasperis said Comstock continues to engage with large customers in the utility segment and has been adding offtake agreements. He said customer demand today is smaller than what the company expects as deployed solar panels mature and reach end of life.

Asked about competitors, De Gasperis said the company still sees alternatives such as landfilling or shredding panels and shipping materials overseas, but said Comstock does not see another company with a comparable science-based system that can produce clean materials and scale to the same extent.

Comstock is also evaluating additional site opportunities. De Gasperis said the company has selected sites two and three, is close to selecting a fourth, and is looking at Ohio, northern Nevada, Texas and the East Coast. He emphasized that site selection is not the same as deploying production capital, and that Comstock will not order equipment for the next facility until the first system is operating and ramping successfully.

The company is also advancing a one-ton-per-day metals recovery pilot system intended to test extraction of silver and other metals from industrial tailings generated by its recycling process. De Gasperis said Comstock hopes to know more about silver recovery before the end of the year, but said it is premature to discuss silver yields.

Sierra Springs Monetization Effort Advances Comstock executives spent a significant portion of the call discussing Sierra Springs, which De Gasperis described as a potentially valuable industrial land and infrastructure opportunity in northern Nevada. He said the consolidated land, water and power position is intended to attract counterparties involved in major industrial and compute-related development.

De Gasperis said Sierra Springs has secured an initial precedent agreement tied to 50,000 dekatherms per day of natural gas, which he said could translate to up to 300 megawatts of power. He said Comstock is also positioned for a potential follow-on opportunity that could bring the total to at least 1.2 gigawatts, though the later opportunity has not yet come to formal bid.

De Gasperis said the company expects to launch a marketing effort later this summer and believes it can structure transactions before year-end, although he noted that potential counterparties may require 90 to 150 days of due diligence.

Bioleum Strategy Recalibrated De Gasperis said Bioleum has been operating more quietly as Comstock prioritizes the metals business, the mining asset sale and Sierra Springs. He said Bioleum’s strategy has been recalibrated following the acquisitions of RenFuel and Hexas, with a focus on integrating feedstock and conversion technologies into a “farm-to-fuel” platform.

De Gasperis said the company does not expect revenue from Bioleum generating fuels in 2027, but does expect revenue from Bioleum generating materials for fuels and from Hexas. He also said Comstock expects to pursue capital at the subsidiary level, potentially through non-dilutive sources and third-party investment, before the end of the year.

Asked about Bioleum impairments recorded in the quarter, De Gasperis said they were non-cash and tied to intellectual property that is no longer strategic to Bioleum’s focused plan. Merrill said the company’s investment carrying value increased to approximately $67 million even after the non-cash impairment.

About Comstock (NYSEAMERICAN:LODE)Comstock Mining, Inc NYSE: LODE is a growth-oriented mineral exploration and production company focused on the historic Comstock Lode in Virginia City, Nevada. The company’s primary business activities include the development, extraction and sale of gold and silver from its flagship Lucerne project. Comstock leverages modern mining techniques and infrastructure to access high-grade ore bodies in one of North America’s most renowned silver-gold districts.

In addition to its core precious metals operations, Comstock Mining maintains a commercial real estate division centered in Virginia City’s historic district.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Comstock Right Now?Before you consider Comstock, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Comstock wasn't on the list.

While Comstock currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
2026-07-24 04:44 8d ago
2026-07-23 23:23 8d ago
ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Futu Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - FUTU
FUTU Futu Holdings
FMP Stock News
Original source text
New York, New York--(Newsfile Corp. - July 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Futu Holdings Limited (NASDAQ: FUTU) between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), of the important August 25, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Futu class action, go to https://rosenlegal.com/cases/futu-holdings-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Futu was not in compliance with the requirements of the China Securities Regulatory Commission (the "CSRC"), including because Futu continued to conduct securities business, public fund sales business and futures business in mainland China without obtaining the requisite licenses or approval; (2) as a result, Futu was reasonably likely to face regulatory penalties, including the disgorgement of ill-gotten gains and other penalties; (3) as a result of the foregoing, Futu's financial results were overstated; and (4) as a result of the foregoing, defendants' positive statements about Futu's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Futu class action, go to https://rosenlegal.com/cases/futu-holdings-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306350

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us